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Abstract 
Trypanosomatids are eukaryotic parasites that migrate between insect 
vectors and mammalian hosts. They cause a number of serious diseases 
with major impacts on human health on a global scale. One example 
is Leishmania, which causes Leishmaniasis, a disease that affects 
approximately 12 million people in Asia, Middle East, Africa, South 
America and Southern Europe. Trans-splicing of trypanosomatid 
polycistronic transcripts produces polyadenylated monocistronic 
mRNAs that are modified at their 5’ends to form the cap4 structure 
(m7Gpppm36,6,2’Apm2’Apm2’Cpm23,2’U). Two trypanosomatid 
translation initiation factor 4E isomers (eIF4E3 and eIF4E4) have 
extended N-terminal regions that include PAM2 motifs; these regions 
can interact with PABC domains in the poly(A)-binding proteins PABP1.  
Using NMR, X-ray crystallography and biophysical quantitation of 
biomolecular interactions, we show that tight binding between 
Leishmania eIF4E4 and PABP1, mediated largely by hydrophobic 
interactions, underpins a novel architecture in the translation factor 
complex bridging the 5’ and 3’ ends of the monocistronic mRNAs. We 
demonstrate that this complex can also accommodate Leishmania 
eIF4G3 which, in contrast to the standard eukaryotic initiation complex 
paradigm, is found to bind to eIF4E4, but not to PABP1. Exceptionally, 
therefore, by binding to two protein ligands and to the mRNA cap4 
structure, the trypanosomatid N-terminally extended form of eIF4E acts 
as a core molecular scaffold for the mRNA-cap-binding complex. Finally, 
our data indicate that the eIF4E4 N-terminal extension is an intrinsically 
disordered region that transitions to a partly folded form upon binding to 
PABP1.
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Chapter 1 – Trypanosomatids, Leishmaniasis and 
the Translation Initiation Complex 
 
1.1: Trypanosomatids and Leishmaniasis 
 
Leishmaniasis 
 
Leishmaniasis is a neglected tropical disease (NTD) that affects a large 
number of countries around the globe, the exceptions being Australia and 
Antarctica (PACE, 2014). The disease is concentrated in countries in 
Southeast Asia, East Africa, the Middle East and Latin America. 
Leishmaniasis is also found in several Mediterranean countries in 
Southern Europe, like France, Italy and Spain (READY, 2010). 
 
According to the World Health Organization, there are over 1 billion 
people living at endemic areas at risk of infection, with 300,000 new cases 
of visceral leishmaniasis every year, and more than 1 million cases of 
cutaneous leishmaniasis reported in the last 5 years - the number of 
deaths exceed 20,000 every year (WHO Weekly epidemiological record, 
2016). The large number of people affected by leishmaniasis makes its 
study of great importance, especially studies whose outcome may help in 
the relief of the burden caused by the disease. 
There are around 53 known Leishmania species, from which 20 are 
pathogenic to humans. The disease is transmitted by the bite of the 
female sandfly from the genera Phlebotomus, in the Old World, and 
Lutzomyia in the New World. 93 of the 800 sandfly species transmit 
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leishmaniasis (PACE, 2014). Among the several Leishmania species, the 
most common are L. major, L. donovani, L. infantum and L. braziliensis. 
Fossil evidence suggests that the first Leishmania appeared during the 
Cretaceous (146-65 MYA), and had reptiles as its main targets. The first 
evidence of humans infected by Leishmania dates from 2000 BC, being 
found in remains of Egyptian mummies; in the new world, archaeologists 
found a 6-year-old girl Peruvian mummy, dated 800 BC, infected with 
leishmaniasis (AKHOUNDI, 2016). 
There are 3 major types of leishmaniasis: Cutaneous, Muco-cutaneous 
and Visceral (Kala-Azar). 
1.1.1: Cutaneous leishmaniasis - CL  
 
Cutaneous leishmaniasis (CL) is the most common manifestation of the 
disease. The disease has a varied incubation period, ranging from weeks 
to months. It has as characteristic the presence of ulcers on exposed 
areas of arms, legs, torso, and often appear in large numbers (BARRETT, 
2012). These start as papules, that after a developing time, ulcerate. In 
some cases, the disease can last for more than two years (DOWLATI, 1996), 
and even after initial cure, relapsing 
can occur (VALESKY, 2007). The 
ulcers caused by CL leave severe 
scars after treated, causing lasting 
effects in the individuals afflicted by 
the disease, even after treatment. 
Figure 1 - Child affected by cutaneous leishmaniasis. Large lesions on the cheek and 
near the nose and eyes. (Photo from WHO website, 
http://www.who.int/leishmaniasis/en/, C. Black). 
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1.1.2: Muco-cutaneous leishmaniasis - MCL 
 
Muco-cutaneous (or mucous) leishmaniasis (MCL) is a disfiguring 
manifestation, and its lesions can partially or totally destroy the mucous 
membranes of the nose, mouth and throat cavities - it has great impact 
on the lives of those affected by MCL (PURSE, 2017). The disease starts 
when the upper respiratory tract is 
infected, displaying cutaneous 
lesions. As the infection aggravates, it 
damages the mucosal tract from oral 
and nasal cavities, even leading to 
nasal septum perforation and 
profound disfiguration (ROYER, 2002).  
Figure 2 - Child affected by muco-cutaneous leishmaniasis. Note the severe damage in 
the nose/ upper lip region. (Photo from WHO website, 
http://www.who.int/leishmaniasis/en/). 
 
1.1.3: Visceral leishmaniasis - VL 
Visceral or Kala-Azar leishmaniasis (VL), whose symptoms are high 
fever, weight loss, swelling of the spleen and liver, and anaemia. VL is the 
most dangerous and potentially fatal variation of leishmaniasis. If left 
untreated, the disease can have a fatality rate of 100% within 2 years 
(PACE, 2014; COLLIN, 2004).  The most characteristic symptoms of VL are 
hepato and splenomegalia, accompanied by weight loss, fever and 
weakness. The disease occurs when the parasites invade the reticulo-
endothelial system, infecting the internal organs cells. (HERWALDT, 1999; 
CHAPPUIS, 2007).  
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Figure 3 - Child affected by visceral 
leishmaniasis. Both spleen and liver are 
massively enlarged, as outlined by green 
markings on the picture. (Photo from WHO 
website, 
http://www.who.int/leishmaniasis/en/). 
 
1.1.4: Epidemiology 
 
According to the World Health Organization, in its 2015 report, 
Leishmaniasis is present in a large number of countries, especially in the 
inter-tropical area. 
 
Figure 4: Leishmania epidemic map, endemic areas are highlighted in red. Data from 
WHO 2015 report. 
 
Leishmaniasis has been identified as a growing concern for international 
travel. Studies have revealed that (MALTEZOU, 2010) there is an 
increasing number of people from non-endemic areas being diagnosed 
with Leishmaniasis. This group contains not only tourists and 
individuals travelling at work (MANSUETO, 2014), but also military 
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personnel deployed in endemic areas or that act in areas in combat 
operations. There are reports from military personnel from the UK armed 
forces and US army based in countries as Iraq, Belize, Panama and 
Afghanistan that were infected with Leishmaniasis. (PREEDY, 2014; 
ROYER, 2002). Leishmaniasis is one of the main parasitic diseases, and 
its mortality rate is only exceeded by malaria (WHO Technical Report, 
2010). 
1.1.5: Sandflies 
 
All types of leishmaniasis are transmitted through the bite of the female 
sandfly. There are two sandfly genera that transmit the disease: 
Phlebotomus in the Old World, and Lutzomyia in the New World. 
According to (PACE, 2014), 93 of the around 800 known sandfly 
subspecies are able to spread leishmaniasis. 
 
Sandfly is an insect that is mostly active at night, in open areas (although 
there are reports of some species that do bite during daytime, indoors). It 
has limited mobility, and its ability to travel vertically has a range of 
around 1.0 metres, and travel horizontally 1500 metres (AKHOUNDI, 2016). 
The first sandlies are believed to have originated during the Eocene (55-
38 MYA), as Phlebotomus, while the separation into 
Phlebotomus/Lutzomyia happened during the Oligocene (38-25 MYA) 
(AKHOUNDI, 2016). 
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1.1.6: Leishmania 
 
The Leishmania parasite was first described in 1900 by the Scottish 
pathologist William Boog Leishman, that was treating British soldiers in 
India. Not long after, the Irish doctor Charles Donovan also identified the 
disease independently.  Their findings led to the discovery of the parasite 
that causes leishmaniasis.  (STEVERDING, 2017).  
 
          (A)                                 (B) 
                            
Figure 5: (A) Lieutenant General Sir William Boog Leishman; (B) Major Charles Donovan. 
(STEVERDING, 2017). 
 
The parasite Leishmania belongs to the Class Kinetoplastida, Order 
Trypanossomatida, Genus Leishmania. It has two main morphologies 
during its lifecycle; a flagellated promastigote and a non-flagellated 
amastigote form. The amastigote cell morphology is smaller, spherical, 
with limited motility. The other cell morphology, promastigote, is larger, 
more elongated, and with a long flagellum, that confers mobility to the 
parasite (SUNTER, 2017). 
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(A)        (B) 
 
Figure 6: Leishmania main morphologies (A) Promastigote (insect); (B) amastigote 
(mammalian host). 
 
The parasite promastigote, flagellated form is found in the sandfly stage 
of the disease. During this period, the parasite develops and multiply in 
the insect gut, and after the sandfly bites the mammal host, and infects 
it. After the host gets infected, the parasite transforms into its amastigote 
form, living mainly in phagocytes of the reticulo-endothelial system. The 
amastigotes then multiple and infect other cells, spreading the infection. 
If the host is bitten by another sandfly, then after the blood meal the 
insect ingests the amastigotes, that then develop into promastigotes in 
the sandfly gut, re-starting the infection cycle (PODINOVSKAIA, 2015; 
CARDOSO, 2015). 
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Figure 7: Leishmania life cycle. (Adapted from the American Center for Disease and 
Prevention website). 
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The Kinetoplastida class has a unique organelle called kinetoplast. 
Kinetoplasts are condensed disks of mitochondrial DNA (kDNA), 
organized in large circles (maxicircles - approximately 20 kb) and small 
circles (minicircles - approximately 1 kb) located in the mitochondria, 
near the flagellum base (POVELONES, 2014). There are around 25-50 
maxicircles and 5000-10000 minicircles, interlocked together in a unique 
disk-shaped structure forming a single kDNA network (VARGAS-
PARADA, 2010). The maxicircles encode genes that correspond to other 
eukaryotic mitochondrial DNA, like subunits of respiratory complex for 
example. However, the maxicircle transcripts are cryptic and require 
further RNA editing, and the minicircles are responsible for controlling 
RNAs that will act in the RNA editing, “correcting” the maxicircle 
transcripts (LIU, 2005). 
 
1.1.7: Nutrition, available treatments, side effects and drug 
resistance  
Several studies suggest that individual’s nutrition plays an important role 
in the occurrence or resistance to leishmaniasis. Malnutrition can lead to 
weakened immune system, putting people in endemic areas in higher 
risk to display the disease (PEREZ, 1979; DIRO, 2015). For instance, studies 
showed that malnutritioned mice showed higher rates of severe VL, 
lower leukocyte count, lower immunological response, suggesting the 
importance of nutrition on resistance to leishmaniasis (CARRILLO, 2014). 
After infection occurs and the clinical symptoms takes place, a number 
of drug treatments are used. The most common drugs used in 
leishmaniasis treatment are Amphotericin B, Miltefosine, Paromomycin 
and Sodium Stibogluconate (LINDOSO, 2012; COPELAND, 2015), although 
other options are also available (CARDOSO, 2014) (Figure 8):  
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(A)        (B) 
          
(C)        (D) 
   
Figure 8: Most common drugs used in leishmaniasis treatment, (A) Amphotericin B; (B) 
Miltefosine; (C) Paromomycin and (D) Sodium Stibogluconate. 
 
Amphotericin B is an antibiotic that is capable of killing Leishmania 
parasites, acting on the parasite’s surface membrane. However, the drug 
is known to cause kidney damage and allergic reactions (WHO 
Frequently asked questions on visceral leishmaniasis kala-azar, 2013). 
Miltefosine was initially developed as an anti-cancer drug, and 
posteriorly tested as anti-Leishmania drug (TIUMAN, 2011). It needs a long 
treatment, and cannot be used during pregnancy, since it can cause fetus 
deformity. It can also lead to gastrointestinal problems, and its long half-
life may lead to increased parasite resistance to the drug (WHO 
Frequently asked questions on visceral leishmaniasis kala-azar, 2013). 
Paromomycin is an aminoglycoside antibiotic with anti-Leishmanial 
activity. It has poor oral absorption, and for this reason, requires deep 
intramuscular injections, daily for at least 21 days (TIUMAN, 2011). Sodium 
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stibugluconate is the most traditional drug for leishmaniasis treatment. 
Its mechanism of action is not completely understood, but there is 
evidence that it acts in the parasite’s oxidative pathways (LINDOSO, 2012). 
It is a significantly toxic drug (toxic to liver, kidneys), being heart 
problems and acute pancreatitis particularly dangerous side-effects 
(TIUMAN, 2011; LINDOSO, 2012). 
Among the several side effects related to these drugs, the most serious 
ones are decreased kidney function, liver problems, permanent hearing 
loss, pancreatitis, veins toxicity and cardiac failure. Also, the 
administration of these drugs is often unpleasant, like for example 
through the application very painful intramuscular injections, or through 
intravenous administration that requires hospitalization. For instance, 
sodium stibugluconate and miltefosine requires daily injection for at 
least 28 days, and hospitalization (WHO Frequently asked questions on 
visceral leishmaniasis kala-azar, 2013). 
Table 1: Pros and cons of the main drugs used in leishmaniasis treatment. 
Drug Pros Cons 
Amphotericin B 
Capable of destroying 
the parasites surface 
membrane, killing it. 
Kidney damage, allergic 
reactions. 
Miltefosine 
It can be used to treat 
different types of 
leishmaniasis. 
Long treatment; fetus 
deformity. Requires daily 
injections. Cannot be 
administrated to children. 
Paromomycin 
Alternative treatment, 
can be used in 
combination with other 
anti-leishmanial drugs. 
Poor oral absorption; 
requires painful deep 
intramuscular injections, 
daily for at least 21 days. It 
can cause hearing loss. 
Sodium 
Stibogluconate 
Classical treatment, 
acts in the parasite’s 
oxidative pathways.  
Toxic drug, affects liver, 
kidneys, heart and 
pancreas. 
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Another important aspect related to leishmaniasis is the occurrence of 
cases in which the parasite is resistant to the current drugs available 
(CROFT, 2006). This, associated to a number of unpleasant side effects 
associated to these drugs, make the treatment of leishmaniasis more 
challenging and needs new drugs and strategies to fight the disease. 
1.2: DNA transcription and trans-splicing 
1.2.1: DNA transcription  
Eukaryotic transcription is the process in which information contained 
in DNA is converted into RNA, being the first stage in gene expression. It 
has 3 major steps: transcription initiation, elongation and termination.  
Transcription initiation begins with DNA sequence, called promoter, 
binding to RNA polymerase, starting the transcription process. 
Any required transcription initiation factors also bind at this stage. The 
promoter-RNA polymerase complex goes through structural changes, in 
such way that the DNA starts to unwind, forming a transcription bubble 
of single stranded DNA. The process occurs in the 5’ to 3’ direction and 
requires only one DNA strand as template. 
During elongation, multiple tasks take place simultaneously; RNA 
synthesis is catalyzed, DNA is initially unwinded, then reannealed and 
the RNA product dissociated as the RNA polymerase moves along, and 
finally, the RNA product is proofread, in a process similar to “quality 
control”. 
The final stage, termination, takes place after the RNA polymerase has 
transcribed the whole gene, stopping transcription. At this step, the RNA 
product is released, and RNA polymerase dissociates from DNA. Often, 
well defined DNA sequences trigger transcription termination, however, 
exceptions are common.  (WATSON, 2014).  
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1.2.2: trans-splicing 
Splicing is the process of joining exons in order to form mature mRNA. 
The majority of organisms use a cis-splicing method, in which the 
introns of the same pre-mRNA transcriptome are removed, and its exons 
joined together (LIANG, 2003). 
One remarkable characteristic of trypanosomatids is their use of trans-
splicing. In trans-splicing, exons of distinct pre-mRNA transcripts are 
joined together, in such a way that the mature mRNA is composed of 
exons derived from different origins. Although “normal” cis-splicing is 
observed in a few genes in trypanosomatids, trans-splicing is responsible 
for almost the totality of mRNA formation. 
 
Splicing requires a short RNA sequence called the Splice Leader RNA (SL 
RNA), that provides the RNA cap, needed for translation initiation. In 
trypanosomatids, the SL RNA has around 141 nt, of which 39 nt comprise 
the SL exon (LASDA, 2011). 
 
Mechanistically, trans-splicing needs SL RNA and pre-mRNA. Typically, 
the SL exon is followed by a GU dinucleotide sequence (5’ splice site), 
while in the pre-mRNA, there is an A nucleotide that acts as the 
Branching Point (BP), followed by a polypyrimidine tract, responsible for 
spliceossome assembly, and before the exon sequence an AG 
dinucleotide sequence (3’ splice site). 
 
The SL RNA initially transfers part of the pre-mRNA BP via its 5’ splice 
site, having its 3’ end hydroxylated. Subsequently, the SL RNA then fuses 
to the pre-mRNA exon, via the 3’ splice site, in such way that at the end 
of this process two products are obtained: a mature mRNA (SL-exon) and 
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a Y-structured intermediary, that will undergo debranching and 
degradation. Figure 9 illustrates this mechanism. 
 
Figure 9:  Mechanism of trans-Splicing (adapted from LIANG et al, 2003). (A)Initial 
components for trans-splicing; (B) first step of trans-splicing; (C) second step of trans-
splicing, with Y-structures intermediate and mature RNA formation. 
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1.3: Trypanosomatid Translation Initiation Complex 
Gene expression leading to protein synthesis is a vital process in all 
organisms, and requires a transcription stage, followed by translation. 
The translation stage is composed of four essential processes: initiation, 
elongation, termination and recycling. 
 
Figure 10: Overview of gene expression leading to protein synthesis. 
 
Protein synthesis has a very important role in gene expression. Its first 
stage, translation initiation, is believed to be the most important point in 
mRNA translation regulation, and therefore is commonly the main focus 
of such studies. 
In translation initiation, the ribosome is recruited to the mRNA and, with 
the aid of multiple initiation factors, a start codon is located. In 
elongation, a protein chain is synthesized from amino acids on the basis 
of a code in the RNA and in termination the polypeptide is released and 
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in recycling the ribosomal complex on the mRNA is disassembled and 
prepared for a new round of translation.  
It is believed that translation initiation is the main control stage in the 
process of protein synthesis, since it consumes a very large amount of 
energy, with works describing the production of more than 10000 protein 
molecules per cell, every second (FIRCZUK, 2013; VON DER HAAR, 2008). 
For this reason, studies that focused on translation initiation might 
provide very important biological data, that can be used, for example in 
the identification of new therapeutic targets. 
 
The trypanosomatid translation initiation complex has unique 
characteristics, and has its parts assembled in a different way than 
observed in other eukaryotes.  
 
Of particular relevance to the present study is the observation that a 
strong interaction between the translation factors eIF4G and PABP1 plays 
a significant role in the translation machineries of eukaryotes other than 
the trypanosomatids. Figures 11 and 13 display the proposed models of 
translation initiation complex, for higher eukaryotes and 
trypanosomatids (adapted from ZINOVIEV, 2012). 
 
1.3.1: The Eukaryotic Translation Initiation Complex 
mRNA translation initiation is a complex, multi-step process that 
involves many different initiation factors. A brief summary of the most 
relevant factors is presented below:  
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Figure 11: Model of higher eukaryotes translation initiation complex. Adapted from 
SHAPIRA, 2012. 
 
eIF4E 
Initiation factor eIF4E is responsible for m7GDP binding, being therefore 
known as the “cap-binding” protein. The eIF4E structure is described as a 
“cupped hand” that holds the cap structure, and this binding enables the 
subsequent scanning process that leads to identification of a start codon 
(HINNESBUSCH, 2012). 
 
PABP 
PABP - Poly(A) Binding Protein binds to the mRNA poly(A) tail and plays 
a role in stabilizing it. PABP has two major sectors: a RNA recognition 
sector, comprising four RRM (RNA Recognition Motif), followed by a poly-
glycine linker, that leads to the PABC domain. PABP also binds to eIF4G 
and eRF3, and in so doing is thought to act as a type of 'scaffolding' 
protein, bringing multiple factors together (compare eIF4G below). PABP1 
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is involved (together with eIF4F) in circularizing mRNA by binding to its 
3’ poly(A) tail, and simultaneously to the eIF4F complex (that in its turn 
binds to the 5’ end of mRNA) (HINNEBUSCH, 2012). 
 
eIF4G 
eIF4G plays a recognized role as “scaffolding” protein. The reason for this 
is that it binds to several translation initiation factors, including eIF4E, 
PABP eIF4A, eIF1, eIF5, among others. This major role as a recruitment 
hub for other proteins assemble onto RNA, in such way that the mRNA 
circularizes by virtue of an interaction chain: 5'cap-eIF4E-eIF4G-PABP-
poly(A) tail (KAPP, 2004). 
 
eIF4A 
eIF4A is an ATP-dependent DEAD RNA helicase, that is thought to act by 
removing secondary structure from the mRNA 5’-UTR region. 
 
eIF2 
eIF2 is involved in ternary complex formation, which comprises eIF2, 
GTP and Met-tRNA. The ternary complex binds to the 40S subunit, thus 
helping to prepare the ribosomal subunit for start codon recognition. 
 
eIF3 
eIF3 is the largest translation initiation complex, comprising to up to 
thirteen subunits, depending on the organism (in L. major, 8 subunits, 
around 480 kDa; in humans, 13 subunits, around 800 kDa). Its activity is 
related to ribosomal subunit recruitment, and it also participates in a 
multiple number of different steps in translation initiation. It binds to the 
40S subunit and promotes the subsequent mRNA scanning. 
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eIF4B 
eIF4B is a RNA-binding factor related to eIF4A, enhancing its helicase 
activity. It is also involved in mRNA recruitment to the preinitiation 
complex (PIC), that is composed of MettRNA, eIF1, eIF1A, eIF2 and eIF3. 
 
eIF1, eIF1A and eIF5 
eIF1 and eIF1A are a translation initiation factors that are part of the 43S 
PIC. They are described as being involved in 43S PIC “open conformation” 
stabilization. Their activity is required for the correct ribosomal scanning 
and codon selection. eIF5 is a GTPase-activating protein, involved in 
initiation codon recognition, interacting with the 40S ribosomal subunit. 
eIF5 binds to eIF2, inducing GTP hydrolysis during initiation codon 
recognition. (HINNEBUSCH, 2012). 
 
 
eIF4F complex  
The eIF4F complex is composed of eIF4E, eIF4G and eIF4A, and is 
responsible for 40S recruitment and is involved in cap-dependent 
translation initiation. 
 
As described above, translation initiation requires a significant number 
of translation factors, that are needed for mRNA assembly and further 
codon screening. This is a very complex process, and Figure 12 
summarizes some of the main protein-protein interactions (interactome) 
involved in translation initiation. 
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Figure 12: Simplified translation initiation complex interactome. 
 
Among all the translation initiation factors, there are three that are 
particularly important in this work: eIF4E, PABP and eIF4G. In almost all 
eukaryotes, eIF4G acts as a “scaffold” factor, assembling a large number 
of different factors. However, in trypanosomatids, it is proposed that 
these interactions might be assembled differently, and as will be 
demonstrated in this work, an interaction between PABP and eIF4E. 
 
Translation initiation has as one of its main steps the assembly of the PIC 
and screening for the start codon; in cap-dependent translation initiation, 
eIF4E binds to the mRNA’s cap-structure, at the 5' end, while PABP binds 
to the mRNA’s poly(A) tail, aiding in mRNA circularization. As mentioned 
above, in trypanosomatids, the interactions of the translation factors 
suggest that the translation initiation complex is assembled in a different 
way, with eIF4E interacting with PABP.  
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Trypanosomatids have multiple translation initiation factors isomers, 
and in the specific case of Leishmania, there are six eIF4E isoforms, two 
PABP isoforms and five eIF4G isoforms. 
1.3.2: Leishmania eIF4E, PABP and eIF4G isoforms 
Several Leishmania translation initiation proteins have multiple 
isoforms. For instance, L. major has 6 eIF4Es, 3 PABPs and 5 eIF4Gs. A 
summary of these proteins is presented below. 
 
eIF4E 
Leishmania has six eIF4E isoforms, eIF4E1 to eIF4E6, all located in the 
cytoplasm (FREIRE, 2017). The literature contains data regarding the first 
four isoforms, while little is known about the last two, more recently 
identified isomers. The eIF4E factors are expected to bind to both RNA’s 
m7GTP and methylated cap-4. 
 
Figure 13: m7GTP-cap-4 structure. 
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The literature shows that (ZINOVIEV, 2012; FREIRE, 2017) eIF4E1-6 have 
different affinities toward m7GTP and cap4. 
 
Table 2 Trypanosomatid eIF4Es affinities and L. major eIF4Es sizes. 
 L. major 
eIF4Es Binds To 
Isoform Size/kDa m7GTP cap-4 
eIF4E1 23.8 ✓ ✓ 
eIF4E2 31.4 X ✓ 
eIF4E3 37.7 ✓ X 
eIF4E4 48.1 ✓ ✓ 
eIF4E5 23.9 ✓ ✓ 
eIF4E6 23.2 ✓ ✓ 
 
A particular feature in the isoforms eIF4E3 and eIF4E4 is the presence of 
a long, unique N-terminal segment, found only in trypanosomatids. The 
function of this longer N-terminal is not completely clear, and therefore, 
has been the object of considerable speculation. One major characteristic 
of this N-terminal extension is the lack of structure, possibly due to the 
presence of a large number of prolines in its sequence, since these are 
expected to destabilize secondary structure formation. eIF4E5 and 
eIF4E6 are the most recently described and least studied of the 
trypanosomatid eIF4Es. These are the small isoforms, with eIF4E6 being 
the smallest, and have limited homology with the other isoforms. 
 
The existence of a number of eIF4E isoforms suggest that each version 
might have a different role during trypanosomatids life span. It has been 
identified in Leishmania (MCNICOLL, 2005) differences in gene 
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expression depending on the parasite developmental stage, in such way 
that genes responsible for some of the eIF4E isomers (but not all) 
expression had their expression increased in the amastigote stage (but 
not in the promastigote).  
There were several attempts in the literature to identify the different 
functions of each of eIF4E isoforms, and a summary is presented below 
(FREIRE, 2017).  
 
eIF4E-1 
Previous studies have revealed (YOFFE, 2006) that eIF4E-1 levels are 
significantly higher in amastigotes than in promastigotes. These 
variations might be associated with differences in environmental 
changes in temperature, since amastigotes are found in the mammalian 
host (higher temperatures), and axenic cultures of promastigotes 
cultivated at higher temperatures undergo a morphology change, losing 
the flagellum and becoming more rounded, amastigote-like. The 
expression of the other isoforms did not show significant differences 
with temperature variation. 
 
eIF4E-2 
Little is known regarding eIF4E2 function, but in trypanosomatids studies 
suggest that it may not be involved in translation (FREIRE, 2017). It binds 
to cap-4 but not to m7GTP, and it is suggested that it might be associated 
with histone mRNA stem-loop binding protein interactions (FREIRE, 
2017). 
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eIF4E-3 
eIF4E-3 binds to m7GTP but not to cap4, and for this reason it is unlikely 
that it is the essential basal isoform (i.e. the one essential for cell survival) 
for trypanosomatid translation initiation. If eIF4E-3 is knocked out, cell 
death takes place both in promastigotes and amastigotes, and there are 
indications that it participates in translation, at least in promastigotes 
(FREIRE, 2011). 
 
eIF4E-4 
eIF4E-4 is the largest eIF4E isoform in trypanosomatids, and its long N-
terminal sequence largely contributes to its increased size. This N-
terminal sequence is not observed in any other eukaryotes, being unique 
to trypanosomatids. It has a high proline content, and it has been 
suggested that it is intrinsically disordered. These properties make the N-
terminal region of eIF4E4 an important subject of research seeking to 
understand its function and behaviour. eIF4E-4 binds both to m7GTP and 
cap-4, and its knockout leads to cell death in amastigotes and arrests 
translation and impairs cell viability in promastigotes.  
 
eIF4E-5 and eIF4E-6 
There is little information available about the roles of eIF4E5 and eIF4E6. 
Initial studies indicate that both proteins are probably involved in 
trypanosomatid cell motility and in procyclic flagellar attachment. This 
hypothesis has its origin in knockout experiments, since after eIF4E-5 
knockout cells displayed impaired motility (swimming), while an eIF4E-
6 knockout leads to flagellar detachment. However, more studies are 
required in order to obtain a clearer image of their respective functions. 
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PABP 
Trypanosomatid PABPs have a highly conserved structure, composed of 
4 RRMs in the N-terminal, a non-conserved linking region, and a 
conserved PABC domain, in the C-terminal region (DA COSTA LIMA, 
2010). In normal conditions, all three isoforms are found in the cytoplasm, 
with only marginal amounts being detected in the nucleus. 
 
PABP1 
The PABP1 is the isoform with the major translation initiation activity, 
being found in the cytoplasm. PABP1 is responsible for mRNA binding, 
through its RRM domains. It interacts with eIF4G3, and thus participates 
in eIF4F complex function (although it is not part of the eIF4F complex).  
 
PABP2 and PABP3 
PABP2 and PABP3 are believed to not to participate in translation 
initiation, being probably involved in other regulatory functions (DA 
COSTA LIMA, 2010). Experiments in which transcription was inhibited, 
both PABP2 and PABP3 accumulated in the nucleus, although not directly 
associated to the chromatin (BATES, 2000). It has been also suggested 
that PABP2 may play an important role in mRNA metabolism and 
regulation (DA COSTA LIMA, 2010; BATES, 2000). PABP3 was not studied 
in detail, so many aspects of its properties and functions are still to be 
determined. 
 
eIF4G 
Trypanosomatid eIF4Gs have in common the presence of a conserved 
MIF4G domain, characteristic to all eIF4Gs (DHALIA, 2005). They can also 
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be divided into two groups with specific characteristics, as described 
below: 
 
eIF4G1, eIF4G2 and eIF4G5 
eIF4G1, eIF4G2 and eIF4G5 have so far not been linked functionally to 
translation initiation. They bind to eIF4E5 and eIF4E6 (FREIRE, 2014-1), 
and their functions are not yet clear, although it is suspected that they 
might have regulatory roles (FREIRE, 2014-2).  
 
eIF4G3 and eIF4G4 
eIF4G3 and eIF4G4 have been described as participating in translation 
initiation (DHALIA, 2004). Besides the characteristic MIF4G domain, the 
two proteins share several conserved segments, and its N-terminal is the 
most relevant. Both eIF4G3 and eIF4G4 have very short N-terminal 
regions, of only around 50 residues and 75 residues, respectively. This 
contrasts with the long eIF4Gs N-terminals from yeast (600 residues) and 
humans (700 residues) (MOURA, 2015).  
1.3.3: Translation Elongation 
Translation elongation is the most conserved step in protein translation 
(KAPP, 2004; DEVER, 2012), and its mechanism is very similar in different 
organisms, from bacteria to eukaryotes. 
Elongation requires that tRNA binds to the ribosomal A site, in such way 
that the ribosome enables in peptide bond formation (given that the 
appropriate tRNA is present). The next step involves the movement of the 
next codon into the A site, and then having the next peptide bond 
formation. This step is repeated until a stop codon is found, and 
termination happens. 
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1.3.4: Translation Termination 
When a stop codon is found during the elongation process, the nascent 
peptide is released from the ribosome. The ribosomal subunits can then 
be recycled, and then used in the formation of a new initiation complex, 
for the production of another peptide (KAPP, 2004).  
1.3.5: Recycling 
The last step in translation initiation is recycling. In this step, the 
ribosomal subunits are disassembled, and then used for a new round of 
translation initiation. During this process, there is the release of mRNA 
and tRNA (KAPP, 2004). 
1.4: MLLE Domains and PAM2 motifs 
1.4.1: MLLE Domain  
The MLLE domain is a well-known peptide binding motif, composed of 
around 70 aminoacid residues, organized in five α-helices. The MLLE, 
also called “mademoiselle” domain is present in several protein, 
including PABP proteins (XIE, 2014). Although the MLLE domain 
comprises usually around 70 amino acids in its sequence, the highly 
conserved KITGMLLE sequence is particularly relevant (KOZLOV, 2010), 
since this has an important role in binding to the PAM2 peptide sequence, 
through its interactions with the correspondent amino acid present in 
the ligand. 
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1.4.2: PAM2 Motif  
The PAM2 motif, or PABP-interacting Motif 2, recognizes proteins 
containing the MLLE domain, and has the following conserved amino 
acid sequence: 
 
(L/P/F)x(P/V)xAxx(F/W)xP  (1) 
Or commonly: 
LNxxAxEFxP    (2) 
 
The PAM2 motif binds to MLLE domains by interacting with hydrophobic 
pockets that are formed along the MLLE domain α-helices. There are 
three amino acid residues in particular in the PAM2 motif that are 
important for the binding to MLLE, the first conserved leucine, and the 
conserved alanine and phenylalanine (KOZLOV, 2010; XIE, 2014).  
1.4.3: PAM2/MLLE Interaction 
 
The PAM2 residues interact with a number of amino acid residues in 
MLLE domains (KOZLOV, 2010). However, as described previously, the 
first conserved leucine, the conserved alanine and the conserved 
phenylalanine are particularly relevant. The leucine and phenylalanine 
bind to hydrophobic pockets located in the α-helices around the central 
α-helix in the MLLE domain, while the PAM2 conserved alanine exploits 
the space left by the central glycine in the KITGMLLE sequence to link the 
two hydrophobic pockets. One example of interacting partners in which 
the PAM2 motif plays a key role is the PABP1/eRF3 complex, involved in 
translation termination (ALBRECHT, 2004; OSAWA, 2012). 
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Figure 14: PAM2 key residues interacting with MLLE domain; hydrophobic pockets 
highlighted in dark blue. 
 
The MLLE domain is well conserved, and studies indicate that it does not 
undergo significant conformational changes for PAM2 binding, being 
completely pre-formed for PAM recognition. 
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1.5: Objectives 
 
1.5.1: General Objectives 
 
1. To investigate the architecture of the trypanosomatid translation 
complex comprising eIF4E4, PABP1 and eIF4G3. Trypanosomatid 
eIF4E4 has a unique, long N-terminal, making it an interesting 
object of research, that could potentially be used as a drug target, 
since these interactions are not observed in humans. 
1.5.2: Specific Objectives 
 
1. To characterize the interactions between Leishmania major 
eIF4E4, eIF4G3, and PABP1. 
 
2. To characterize structural details of the eIF4E4-PABP1 interaction. 
 
3.  To quantitate the relative affinities of the eIF4E4-PABP1 and the 
PABP1-eIF4G3 interactions. 
 
Chapter 2 | Techniques Overview – Materials and Methods 
 
 - 31 - 
Chapter 2 – Techniques Overview - Materials and 
Methods 
2.1: Buffers List 
 
A number of buffers were used in the various experiments, their names 
and composition are listed below: 
 
Buffer A: 
150 mM KCl 
10 mM Tris-HCl pH 8 
10% glycerol 
10 mM MgCl2 
10 mM β-Mercaptoethanol 
 
Buffer B: 
150 mM KCl 
10 mM HEPES pH 7.5 
5% glycerol 
1 mM DTT 
 
 
Buffer C 
150 mM KCl 
20 mM Tris-HCl pH 7.5 
5% Glycerol 
10mM MgCl2 
5 mM β-Mercaptoethanol 
0.01 % Triton X-100 
 
Buffer D 
100 mM KCl 
20 mM Tris-HCl pH 7.5 
10 mM MgCl2 
5% Glycerol 
 
Buffer E 
300 mM KCl 
40 mM Tris-HCl pH 7.4 
2 mM EDTA 
0.1% Triton X-100 
5% Glycerol 
5 mM β-Mercaptoethanol 
1 mM PMSF 
 
Buffer F 
50 mM HEPES pH 7.5 
100 mM NaCl 
1 mM DTT 
0.01% sodium azide 
0.1 mM EDTA 
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2.2: Constructs Preparation 
 
Our studies aimed the investigation of interactions between 
Leishmania’s eIF4E4 and PABP1 proteins. eIF4E4 is a 48kDa protein from 
Leishmania major, that binds to mRNA’s cap structure, and presents the 
following primary structure: 
 
           10        20        30        40        50 
MSTPLDVRAAEYSPSFAVTMKKTVAAAPPKSPAPAKSKISVTRTGVNTTY 
         60         70         80         90        100 
PMPPPMPEKNYAPFFAEGCQTIAASKASMPPVQPASPLPPMHSAPPTASV 
        110        120        130        140        150 
VSNSIPPSSPATAPGERSPAVAARSVPTRFSPATVPRHHMNPNATEFMPG 
        160        170        180        190        200 
RRNGPDGGLEALPTSTADMELAKTPAGAAAAAVHAPSLPGAVRRSLQNSP 
        210        220        230        240        250 
IIQPSRLSVKSASEIEAISKNSALNAAAAAYVPQRTLARVVLTQPSPLAL 
        260        270        280        290        300 
APSEDPAKNNIEMMLDDLWCLFYLPTTLGENIKEEDYNPTLVFRVDSILT 
        310        320        330        340        350 
FWRVVNNIAAPSELQLSTLYLFRDGIDPKWEDPANRDGGIVKVKATAAQV 
        360        370        380        390        400 
DEAWELLLCRTIGDSWSPSVRETVNGVVLKVRERAYWLELWVTKNSSALQ 
        410        420        430        440    447 
KDLAELWHPILGASFATTYLTHAMMQERSHAAAALAAEKQKKNRRRY 
  
 
 Figure 15: Leishmania eIF4E-4 segmentation in several domains. 
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PABP1 is a 62kDa protein from Leishmania major, that binds to mRNA’s 
poly(A) tail, and presents the following primary structure:  
 
        10        20        30        40        50  
MAAAVQEAAAPVAHQPQMDKPMQIASIYVGDLDATINEPQLVELFKPFGT 
        60        70        80        90       100 
ILNVRVCRDIITQRSLGYGYVNFDNHDSAEKAIESMNFKRVGDKCVRLMW 
       110       120       130       140       150 
QQRDPALRYSGNGNVFVKNLEKDVDSKSLHDIFTKFGSILSCKVMQDEEG 
       160       170       180       190       200 
KSRGYGFVHFKDETSAKDAIVKMNGAADHASEDKKALYVANFIRRNARLA 
       210       220       230       240       250 
ALVANFTNVYIKQVLPTVNKDVIEKFFAKFGGITSAAACKDKSGRVFAFC 
       260       270       280       290       300 
NFEKHDDAVKAVEAMHDHHIDGITAPGEKLYVQRAQPRSERLIALRQKYM 
       310       320       330       340       350 
QHQALGNNLYVRNFDPEFTGADLLELFKEYGEVKSCRVMVSESGVSRGFG 
       360       370       380       390       400 
FVSFSNADEANAALREMNGRMLNGKPLIVNIAQRRDQRYTMLRLQFQQRL 
       410       420       430       440       450 
QMMMRQMHQPMPFVGSQGRPMRGRGGRQQLGGRAQGHPMPMPSPQQPQAP 
       460       470       480       490       500 
AQPQGFATPSAVGFVQATPKHSPGDVPETPPLPPITPQELESMSPQEQRA 
       510       520       530       540       550 
ALGDRLFLKVYEIAPELAPKITGMFLEMKPKEAYELLNDQKRLEERVTEA 
       560 
LCVLKAHQTA 
 
 
The PABP1 was divided into subdomains, using its natural architecture 
as guide. The segmentation into smaller subdomains would be used as a 
toolkit, allowing the investigation and screen of the different PABP1 
regions, in such way that it would be possible to analyze how they would 
behave when subjected to binding experiments. For instance, subdomain 
PABP1(A) explored the first two PABP1 RRM domains, while the 
subdomain PABP1(J) corresponds to the PABC domain. 
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Figure 16: Leishmania PABP1 segmentation in several domains. 
 
2.2.1: Restriction based cloning and Gibson assembly 
 
Subcloning: 
Cloning technique was used in order to obtain some of the vectors for 
protein expression. 
The cloning procedure was performed as follows: 
The gene of interest was amplified using primers with 5’ overhangs 
containing the desired restriction sites. 
The amplified insert and the target vector were then digested with the 
appropriate restriction enzyme. Unless otherwise stated, the restriction 
enzymes BamHI and HindIII were used in all cloning. 
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Insert and vector purification was performed using Thermo Scientific 
GeneJET Plasmid Purification kit, and if required, gel extraction was done 
using Thermo Scientific GeneJET Gel Extraction Kit. 
The insert was digested using 100µL reactions, composed by 10µL of 
digestion buffer (specific to the restriction enzymes used), and 2µL of 
each restriction enzyme, and 88µL of nuclease-free water. The vector was 
digest also in 100µL reactions, composed by 10µL of digestion buffer 
(specific to the restriction enzymes used), and 2µL of each restriction 
enzyme, 10µL of vector and 78µL of nuclease-free water. The reactions 
were then incubated at 37˚C for 1 hour. 
Vector dephosphorylation was made by adding 1µL of FastAP 
Thermosensitive Phosphatase (Fermentas), incubated at 37˚C for 15 
minutes, and inactivated by incubation at 75˚C for 5 minutes. The 
products were then purified using Thermo Scientific GeneJET Plasmid 
Purification kit and used for ligation. 
The insert/vector ligation was performed in 10µL reactions, using 1µL of 
10*NEB Ligase buffer, and the appropriate volume of vector/insert in 
order to achieve a 1:3 vector/insert molar ratio; then 1µL of T4 ligase, and 
enough nuclease-free water to total 10µL. 
The mixture was incubated at room temperature for 30 minutes, ant then 
transformed into E. coli. 
 
 Gibson Assembly: 
The Gibson Assembly technique was used in order to obtain some of the 
vectors for protein expression. The Gibson Mix (5x Isothermal Reaction 
Mix) has the following components: 
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5x Isothermal Reaction Mix 
-Tris-HCl pH 7.5: 500mM 
-MgCl2: 100mM 
-dATP: 1mM   
-dCTP: 1mM 
-dGTP: 1mM 
-dTTP: 1mM 
-DTT: 50mM 
-PEG8000: 30mM 
-NAD: 5mM 
-ddH2O to the desired volume
 
1.33x Assembly Master Mix 
Protocol for 1.2 mL of Master Mix: 
-320μL 5X Isothermal Master Mix 
-0.64μL 10 U/μL T5 exonuclease  
-20μL 2 U/μL Phusion DNA Pol  
-0.16μL 40000 U/μL Taq DNA 
Ligase  
-860μL ddH2O
  
For the reaction, 15µL of Gibson Master Mix was added to 2.5µL of 
digested vector, and then split in two 7.0µL aliquots, A and B. To aliquot 
A, 1.0 µL of sterile, nuclease-free water was added, to be used as negative 
control. To aliquot B, 1.0 µL of 10µM GeneBLOCK was added, and then 
incubated in a thermocycler at 50˚C for 30 minutes. After the reaction 
ended, 2.0 µL of the reaction was transformed into competent cells and 
plated on selective media. The Figure 17 summarizes the procedure. 
 
 
Figure 17: Gibson Assembly procedure summary. 
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2.2.2: E. coli transformation 
 
E. coli transformation for protein expression was performed as follows: 
The appropriate amount of competent cells were thawed and added into 
a single sterile 1.5mL Eppendorf tube. In another tube, 1.0 µL of vector was 
added, and then 40-70µL of competent cells were then added to the 
vector. 
The tubes were then incubated on ice for 10 minutes, and then heat-
shocked for 30 seconds at 42˚C. The tubes were then cooled down on ice 
for 1 minute, and 0.5-1.0 mL of sterile LB/SOC media added to the tubes, 
which were then incubated for 30-60 minutes at 37˚C. Finally, the cells 
were plated on selective media (LB-agar + antibiotic) and incubated 
overnight at 37˚C. 
 
2.2.3: Protein overproduction 
 
All proteins were prepared as follows, unless stated otherwise: 
  
The media chosen for protein expression was Terrific Broth with 25 mM 
Ampicillin. When the OD600 reached 0.6-0.8, enough IPTG was added to 
reach 1.0mM concentration. The overexpression was conducted at 16˚C, 
for 16h. 
The cells were then pelleted by centrifugation at 10000 rpm for 45 
minutes at 4˚C in a Beckman-Coulter Avanti J-26 XP centrifuge using JLA 
8.1 rotor, and then lysed through 10 cycles of 30 seconds sonication/ 1 
minute rest, on ice. 
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After sonication, the cells were pelleted by centrifugation at 16000 rpm 
for 30 minutes at 4˚C in a Beckman-Coulter Allegra 64R centrifuge using 
F0685 rotor. The supernatant was collected and then used for protein 
extraction and purification. 
 
2.3: Protein purification 
Protein purification was performed using a combination of methods, 
essentially affinity and size exclusion. 
 
2.3.1: Affinity purification 
The supernatant obtained in the protein overproduction stage was 
incubated overnight with cobalt resin (HisPur, Thermo Fisher Scientific). 
After the incubation, the resin was washed thoroughly and then eluted 
with at least 10 1.0mL elutions of Buffer A with 150 mM imidazole. The 
elution aliquots were then joined into a single sample, and then 
concentrated using Sartorius Vivaspin 3000 MWCO PES 20mL 
concentrators, filter at 3000 rpm in an Eppendorf 5810R centrifuge using 
S-4-104 rotor until the volume was reduced to 500-1000 µL. The 
concentrated fractions were then used in size exclusion 
chromatography, in order to isolate monomeric protein from any 
aggregates. 
 
2.3.2: Size Exclusion chromatography purification 
The concentrated samples from the affinity purification were subjected 
to exclusion chromatography. For this, 500µL of sample was injected in 
an AKTA FPLC Purifier UPC100 with size exclusion columns Superdex 
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Increase 75/300 GL and Superdex Increase 200/300 GL (depending on the 
protein size), equilibrated with 2 CV until constant mAU, in order to 
separate protein monomers from aggregates (1.0mL loop, emptied with 
0.7mL; flow of 0.3mL/min, 600µL fractions). After gel filtration, the 
fractions containing the protein monomer were, if needed, concentrated 
(but avoiding aggregation), aliquoted and stored at -80˚C for use in the 
various experiments. 
2.4: Protein identification 
In order to verify each step of protein production, it was necessary to 
confirm protein identities. A combination of electrophoresis and mass 
spectrometry was used, according to the stage of protein 
production/purification. 
 
2.4.1: SDS-PAGE 
 
After protein production and purification, these were subject to analysis 
by SDS-PAGE and Mass Spectrometry in order to confirm the success in 
its attainment. 
The protein samples were prepared using Morris Formula Sample Buffer 
prior to electrophoretic run. SDS-PAGE was performed using a BioRad 
Mini PROTEAN TetraCell System, powered by a BioRad PowerPAC200 
power supply. We used precast gradient gels, from Expedeon SDS Precast 
Gels 4-20% and 4-12%, that were run at constant voltage of 100V, for 80 
minutes, and used Expedeon RunBlue Running Buffer. After the 
electrophoretic run, the gels were stained with Expedeon Instant Blue dye 
and then scanned using a GelDoc XR+ Imaging System. 
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2.4.2: Mass spectrometry 
 
The identification of protein identities was performed by mass 
spectrometry, using a nanoLC-ESI-MS/MS approach. For this purpose, 
SDS-PAGE sections containing protein bands of interest were digested 
and analyzed according to the following protocol: 
  
Initially, the bands containing the proteins of interest were cut from the 
SDS-PAGE gels and digested with trypsin, and then the peptides 
separated by reversed phase chromatography. For the separation, two 
columns were utilized, an Acclaim PepMap µ-precolumn cartridge 300 
µm i.d. x 5 mm 5 μm 100 Å and an Acclaim PepMap RSLC 75 µm x 25 cm 
2 µm 100 Å (Thermo Scientific), installed on an Ultimate 3000 RSLCnano 
system (Dionex). Two mobile phases were also used; the mobile phase A 
was composed by 0.1% formic acid in water and mobile phase B 0.1 % 
formic acid in acetonitrile. In the next step, the samples were loaded onto 
the µ-precolumn equilibrated in 2% aqueous acetonitrile containing 0.1% 
trifluoroacetic acid for 8 min at 10 µL min-1 after which peptides were 
eluted onto the analytical column at 300 nL min-1 by increasing the 
mobile phase B concentration from 4% B to 25% over 22 min then to 90% 
B over 3 min, followed by a 10 min re-equilibration at 4% B. 
 
The isolated peptides were then subjected to electrospray ionization and 
analyzed on a Thermo Orbitrap Fusion system (Q-OT-qIT, Thermo 
Scientific). Precursor peptides scanning from 375 to 1500 m/z were 
performed at 120K resolution (at 200 m/z) with a 2 × 105 ion count target. 
Tandem MS was performed by isolation at 1.2 Th using the quadrupole, 
HCD fragmentation with normalized collision energy of 30, and rapid 
scan MS analysis in the ion trap. The MS2 ion count target was set to 3 x 
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103 and the max injection time was 200 ms. Precursors with charge state 
2–6 were selected and sampled for MS2. The dynamic exclusion duration 
was set to 30 s with a 10 ppm tolerance around the selected precursor and 
its isotopes. Monoisotopic precursor selection was turned on. The 
instrument was run in top speed mode with 1 s cycle. 
 
Data Analysis 
The obtained MS raw data was processed using MSConvert in 
ProteoWizard Toolkit (version 3.0.5759)1. All the MS2 spectra were 
searched with Mascot engine (Matrix Science, version 2.4.1) against 
provided Leishmania database and the common Repository of 
Adventitious Proteins Database 
(http://www.thegpm.org/cRAP/index.html). Peptides were generated 
from tryptic digestion with up to two missed cleavages, 
carbamidomethylation of cysteines as fixed modifications, and oxidation 
of methionines as variable modifications. Precursor mass tolerance was 
10 ppm and product ions were searched at 0.8 Da tolerances. 
Scaffold (version Scaffold_4.3.2, Proteome Software Inc.) was used to 
validate MS/MS based peptide and protein identifications. Peptide 
identifications were accepted if they could be established at greater than 
95.0% probability by the Scaffold algorithm. Protein identifications were 
accepted if they could be established at greater than 95.0% probability and 
contained at least 2 identified peptides.  Protein probabilities were 
assigned by the Protein Prophet algorithm (NESVIZHSKII, 2003). Proteins 
sharing significant peptide evidence were grouped into clusters 
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2.5: Surface Plasmon Resonance 
 
Surface Plasmon Resonance is a technique that detects changes of the 
refractive index on a surface upon ligand binding. In this technique, a 
gold-coated chip is covered with a chemical matrix, often dextran, that 
can then be used for a range of different methods of target 
immobilization. Protein-ligand studied can explore a number of different 
immobilization methods, such as amine coupling, thiol coupling, His-tag 
affinity, to mention a few. 
 
The usual strategy involves the immobilization of a target protein on the 
surface chip, using one of the methods aforementioned. After 
immobilization, the ligand binding can then be investigated, by its 
addition at varied concentrations. If the ligand binds to the target protein, 
the local refractive index changes, and this change can be measured by 
changes in the angle of a laser that is irradiating the chip. The refractive 
index change is proportional to ligand binding, and through this measure, 
a number of data can be obtained, as affinity, kon koff rates, among others. 
  
The SPR experiments were performed using a GE Biacore T200 
instrument, and surface-binding chip CM5. 
The immobilization strategy used was amine coupling, using eIF4E4(iv) 
(0.2mM) protein as the ligand, Buffer B, flow-path number 2, until an 
immobilization level of around 1000 units was obtained. 
2.5.1: Yes/No binding experiment 
 
Each Yes/No Binding experiment comprises a sequential run of different 
analytes, in this case PABP1 domains, at the same concentration. This 
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experiment is used to screen a number of ligands and verify if they bind 
to an immobilized partner on the chip’s surface. 
 
Experimental Conditions: 
-Buffer C 
-Regeneration Solution: MgCl2 1M 
-Injection Time: 300 s 
-Regeneration Time: 120 s 
-Dissociation Time: 300 s 
-Cell Flow: 10µL/min 
-Cell Flow Mode: 2-1
 
2.5.2: Binding affinity experiment 
 
The Affinity experiment comprises of the sequential run of different 
analytes, in this case PABP1 domains, at varied concentrations. These 
experiments are useful to assess the binding behaviour of a ligand, and 
in ideal conditions, determine its affinity towards a binding partner. 
Experimental Conditions: 
 
-Buffer C 
-Regeneration Solution: MgCl2 1M 
-Injection Time: 300 s 
-Regeneration Time: 120 s 
-Dissociation Time: 300 s 
-Cell Flow: 10µL/min 
-Cell Flow Mode: 2-1
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 2.6: Microscale Thermophoresis 
 
The MST experiments were performed in a Nanotemper Monolith NT.115 
instrument, using standard Monolith NT.115 Capillaries. Protein labelling 
with fluorescent tag was made using Monolith Protein Labelling Kit Red-
Maleimide. 
MST experiments detects binding on the basis of alterations in thermal 
diffusion when a complex is formed, when compared with the thermal 
diffusion of the individual complex components. 
 
2.6.1: Binding affinity experiment 
The binding affinity experiments were performed by labelling eIF4E4(iv) 
with a fluorescent tag (Monolith Protein Labelling Kit Red-Maleimide), as 
instructed in the kit manufacturer user manual. In this experiment, the 
fluorescent tagged protein (eIF4F4(iv)) is held at constant concentration, 
while the ligand protein (PABP1 domains) concentration is varied. The 
experiment is conducted by preparing 16 tubes with various 
combinations of eIF4E4(iv)/PABP1 domain concentrations. This is 
achieved by serial dilution, and then glass capillaries are added to each 
tube, until they are filled with the respective solutions. The capillaries are 
then loaded on a rack and inserted in the MST equipment for 
measurement. The experiment starts with a quality check, whose main 
parameters are fluorescence homogeneity between the capillaries, 
fluorescence intensity, adsorption, aggregation and ligand-induced 
photobleaching. After the checks, the measurements start, and a graph 
containing the data is plotted, and then a final signal-to-noise evaluation 
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is performed. The final step involves the calculation of affinity constants 
and overall data quality evaluation.  
2.7: Nuclear Magnetic Resonance 
 
Nuclear magnetic resonance (NMR) is a very powerful technique that can 
provide valuable information in protein/protein and protein/ligand 
studies. NMR uses the magnetic properties of active atom isotopes, and 
through a large range of techniques, information regarding structure, 
dynamics and affinity can be obtained. Since the technique requires 
samples that are magnetically active, (i.e. contain magnetically active 
isotopes) the proteins used in this study were prepared as isotopically 
labelled samples.  
The experiments in this thesis were performed in collaboration with the 
group of Prof. Alex Breeze, from the University of Leeds, using a 950 MHz 
Bruker Ascend Aeon™ NMR magnet with TXO-cryoprobe (5mm) and 
equipped with a Bruker Avance III HD console and 600 MHz Oxford NMR 
magnet with QCI-P-cryoprobe equipped with Bruker Avance III HD 
console. 
2.7.1: {1H-15N}-HSQC and TROSY 
 
In the investigation of protein/protein interactions, one of the most useful 
techniques is the HSQC - Heteronuclear Single Quantum Coherence 
experiment. In these 2D experiments, two different types of atom are 
monitored (most commonly the pairs 1H and 13C, or 1H and 15N). 
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In protein studies, {1H-15N} HSQC spectra provide peaks in a way that each 
peak corresponds to one aminoacid residue in the primary structure of 
the protein being studied. 
When a ligand is added to a protein solution, the aminoacid residues that 
are involved in ligand binding can have their chemical shifts changed, 
i.e. the peak can change position (shift) or undergo changes in its 
intensity, often disappearing. 
 
 
Figure 18: Chemical shifts in interacting peaks in a HSQC spectrum simulation. 
 
  
These changes can give very good indications that binding is being 
observed. In order to map the binding interactions in proteins primary 
structure, it is necessary to assign each peak to an aminoacid, which is 
done through a number of triple resonance NMR experiments, which 
allow their assignment. 
TROSY (Transverse relaxation-optimized spectroscopy) is an NMR 
experiment that is often used in the study of larger proteins. When large 
proteins are investigated by NMR, it is very common to observe signal 
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overlapping, making the data analysis difficult. TROSY can help in this 
situation, since it increases resolution and sensitivity (but it requires the 
use of higher magnetic fields). 
 
Figure 19: Diagram comparing the difference between TROSY and non-TROSY 
experiments (Adapted from FERNANDEZ, 2003). 
 
2.7.2: Triple resonance and residue assignment 
 
In order to assign amino acid residues, it is usually necessary, along with 
a HSQC, to perform experiments that will identify the C𝛼, Cβ and CO 
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moieties in each amino acid. Since each peak couples with its 
corresponding neighbour, it is possible to use these couplings for the 
assignments. For this, we need to do HNCA, HNCOCA, HNCACB, 
HNCOCACB, HNCO and HNCACO experiments. Each set of experiments 
will provide information regarding the identity of each amino acid 
residue, observing the amino acid in the position i and in the position i-1, 
for instance. The information associated with the coupling and chemical 
shifts can be used to perform the assignment, with the assistance of the 
appropriate software; for example, CCPN Analysis V2.4.2. 
The triple resonance analysis was performed observing the data from a 
pair of experiments: HNCA/HNCOCA, HNCACB/HNCOCACB and 
HNCO/HNCACO. Below, Figures 20, 21 and 22 summarize information 
regarding each of these experiments (spectra strips and magnetization 
transfer for NMR detection). 
 
(A)     (B)  
 
Figure 20: HNCA and HNCOCA diagrams, (A) HNCA and HNCOCA spectra strips, 
demonstrating the typical profile of each experiment; (B) HNCA magnetization transfer 
diagram; (C) HNCOCA magnetization transfer diagram.  
 
(C) 
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(A)            (B)  
 
Figure 21: HNCACB and HNCOCACB diagrams, (A) HNCACB and HNCOCACB spectra 
strips, demonstrating the typical profile of each experiment; (B) HNCACB magnetization 
transfer diagram; (C) HNCOCACB magnetization transfer diagram.  
 
 (A)          (B)  
 
Figure 22: HNCO and HNCACO diagrams, (A) HNCO and HNCACO spectra strips, 
demonstrating the typical profile of each experiment; (B) HNCO magnetization transfer 
diagram; (C) HNCACO magnetization transfer diagram.  
(C) 
(C) 
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HNCA/HNCOCA experiments provide information regarding a sample’s 
C𝛼. HNCA experiments display two peaks, one relative to the C𝛼 of the 
amino acid residue at the i position, the second relative to the C𝛼 at the i-
1 position. The HNCOCA displays only the C𝛼 at the i-1 position, allowing 
the identification of each residue. Since each HNCA spectrum strip has 
information regarding an amino acid and its predecessor, the 
combination of multiple strips, allied to the characteristic chemical shifts 
of certain residues, allows the linking of the strips to match the protein’s 
primary structure. As an example, alanine commonly has its C𝛼 at around 
18 ppm, whereby and no other amino acid displays similar values at this 
range, allowing unequivocal the identification of alanine.  
 
A similar approach is used with the HNCACB/HNCOCACB and 
HNCO/HNCACB pairs, in a such way that the HNCACO will provide 
information regarding C𝛼 and Cβ at the position i, and also C𝛼 and Cβ at 
position i-1. HNCOCB, however, displays only C𝛼 and Cβ at the position i-
1. In the last pair of experiments, HNCO/HNCACO, the HNCO peaks reveal 
only the carbonyls (CO) at the position i-1, while the HNCACO peaks 
correspond CO from both position i and position i-1. 
These pairs of experiments complement each other, and their 
combination allows the assignment of an HSQC spectrum through the 
connection of multiple strips in a sequential way. 
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Figure 23: Diagram illustrating the process of amino acid residue assignment via triple 
resonance experiments. 
  
Isotopically labelled proteins 
The production of isotopically labelled proteins was performed using an 
Applikon ez-Control Bioreactor, in minimal media containing 
isotopically labelled reagents. 
  
The minimal medium used has the following composition: 
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Isotopically labelled reagents: 
-D-glucose (U13C6, 99%, Cambridge Isotope Labs) 
-Ammonium Chloride (15N, 99%). 
 
Additional Components: 
42.20mM Na2HPO4 
22.0mM KH2PO4 
8.50mM NaCl 
18.70mM 15NH4Cl 
2.00mM MgSO4 
0.01mM CaCl2 
0.01mM FeSO4 
11.10mM 13C-glucose 
2.86µM Choline Chloride 
0.90µM Folic Acid 
2.28µM Pantothenic Acid 
4.09µM Nicotinamide 
5.55µM Myo-Inositol 
2.45µM Pyridoxal.HCl 
1.48µM Thiamine.HCl 
0.13µM Riboflavin 
4.09µM Biotin 
3.00µM (NH4)6(Mo7) 
0.40mM H3BO3 
30.00µM CoCl2 
0.10µM CuSO4 
0.80µM MnCl2 
0.10µM ZnSO4 
The NMR experiments were performed, unless stated, in the following 
conditions: 
 
-Buffer F 
-Temperature: 27˚C 
-Sample concentration: 50-
200µM 
 -Sample Volume: 300uL 
-NMR tube: 10mm Shigemi tube D2O 
matched 
-Deuterium Oxide concentration: 5% 
 
All data analysis was performed using the software Bruker TopSpin 3.5pl7 
and CCPN Analysis V2.4.2 
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Chapter 3 – eIF4E4 and PABP1 protein domains: 
production and purification 
 
Protein production 
 
The initial attempts for protein production were made using 
commercially produced synthetic DNA constructs, manufactured by the 
company DNA2.0. These constructs were designed to encode for 
Leishmania eIF4E4 and PABP1, as well varied domains of each (please 
see details in the Annexes). There were several attempts for the 
production of these proteins, in several conditions, but without success.  
Other strategies were then used in order to obtain the target proteins, for 
instance the preparation of fusion proteins with MBP-12His tag. The MBP 
tag can be used to increase protein solubility (ALEXANDROV, 2001), and it 
contains a C-protease cleavage site. It was possible to obtain a number of 
encoded proteins in these conditions; however, it was not found possible 
to cleave and remove the MBP tag. 
 
 
Figure 24: SDS-PAGE gel with the different MBP-fusion constructs of eIF4E4 and PABP1.  
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The next strategy involved substitution of the MBP tag by the GST tag. 
The GST-tagged constructs were less successful than those made with its 
MPB counterpart, and also displayed the same C-protease cleavage 
issues, rendering it unattractive for use in binding experiments. 
Subsequently, the constructs were cloned into the pET22b vector, and it 
was found possible to obtain two His-tagged constructs, eIF4E4(i) and 
eIF4E4(iv). The eIF4E4(i) corresponds to the eIF4E4 N-terminal region, 
and it was used for antibodies production, but since the main objective 
was to identify the binding motif, eIF4E4(iv) was a better protein domain, 
due to its shorter sequence, especially since it had previously been 
described in the literature as a potential binding region in eIF4E4 
(ZINOVIEV, 2012). After eIF4E4(iv) was obtained and optimized, protein 
production was initially performed by growing E. coli cultures in 2L 
flasks, in the conditions described in the Material and Methods. 
eIF4E4(iv) displayed a marked tendency to aggregate, protein yield was 
generally low. In order to help address these issues, the incubation 
temperature was lowered to 16˚C, giving rise to a limited improvement in 
the aggregation behaviour. Detergents, reducing agents and different salt 
concentrations were also tested, but little further improvement was 
observed. 
 
Figure 25: SDS-PAGE gel of 
eIF4E4(iv), - note the increased 
protein aggregation after 
concentration. 
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The utilization of a bioreactor increased substantially the protein yield. 
Cultures grown in flasks in incubators had a pellet yield of around 4g/L of 
medium, while cultures grown in bioreactors had this yield increased 7-
10-fold. The resulting increase in the size of the pellet generated a greater 
amount of monomeric protein, but there was no increase in aggregation. 
Figure 26 shows the chromatogram of eIF4E4(iv) after size exclusion 
chromatography.  
 
Figure 26: Size exclusion chromatogram of eIF4E4(iv), in Superdex Increase 75 10/300 
GL column. Aggregated protein peak located between the fraction A5-A9; monomeric 
protein peak between fraction A12-A15. Void volume = 7.2 mL, 1 CV= 24 mL; molecular 
weight range= 3-70 kDa. 
 
The large peak corresponding to fractions A5-A10 contains aggregated 
protein, while in a small peak in the fractions A11-A15 corresponds to 
monomeric protein. The column Superdex Increase 75 10/300 has a void 
volume of 7.2 mL, 1 CV is 24mL and the separatable molecular weight 
range lies between 3-70kDa; therefore, anything larger than 70 kDa is 
eluted before 7 mL, while anything smaller that 3 kDa leaves the column 
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after 24mL. As illustrated in Figure 26, the majority of protein is 
aggregated, requiring a larger amount of cell culture or more efficient 
production (as achieved using bioreactors) in order to obtain appropriate 
amount of monomeric protein. Figure 27 displays the SDS-PAGE gel for 
this size exclusion purification. 
 
Figure 27: SDS-PAGE gel of eIF4E4(iv), in Superdex Increase 75 10/300 GL column. 
Aggregated protein peak located between the fraction A7-A9; monomeric protein peak 
between fraction A10-A15. 
 
The protein fractions containing monomeric protein were collected, 
joined in a single sample, and concentrated. The protein concentration 
was determined by the use of SDS-PAGE BSA standards, as shown in 
Figure 28. 
 
Figure 28: SDS-PAGE gel of eIF4E4(iv) concentration determination, using BSA 
standards. Protein concentration is determined by comparing the sample band 
intensity with a calibration curve obtained by the BSA standards. 
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Isotopically labelled protein production 
 
The production of isotopically labelled protein utilized minimal medium, 
as described in the Material and Methods. The protein yield was superior 
to that obtained in rich medium and was suited to requirements. 
 
The large peak between fractions A3-A10 corresponds to aggregated 
protein, while the small peak between the fractions A11-A14 corresponds 
to monomeric protein. Figure 30 displays the SDS-PAGE gel for this size 
exclusion chromatography. 
 
 
Figure 29: Size exclusion chromatogram of isotopically labelled eIF4E4(iv), in Superdex 
Increase 75 10/300 GL column. Aggregated protein peak located between the fraction 
A3-A10; monomeric protein peak between fraction A11-A14. 
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Figure 30: SDS-PAGE gel of isotopically labelled eIF4E4(iv), in Superdex Increase 200/300 
GL column. Aggregated protein peak located between the fraction A10-A14; monomeric 
protein peak between fraction A15-B3. 
 
The isotopically labelled protein fraction containing monomeric protein 
were also collected, joined in a single sample and concentrated. The 
protein concentration was determined by the use of BSA standards, as 
shown in Figure 31, side-by-side to non-labelled eIF4E4(iv). 
 
                                    (A)  (B) 
 
Figure 31: SDS-PAGE gel of (A) non-labelled eIF4E4(iv); (B) isotopically labelled 
concentration determination, using BSA standards. 
 
 
Chapter 3 | eIF4E4 and PABP1 protein domains: production and 
purification 
 - 59 - 
PABP1 domains were prepared by another group member, Dr Maja 
Firczuk, being overproduced in E. coli with an N-terminal 12His-tag, and 
in most cases purified using cobalt affinity, followed by size exclusion 
chromatography, as described in the methods. For a few proteins, like full 
length PABP1, PABP1(A) and PABP1(B), the yield was too low to proceed 
with size exclusion chromatography. 
 
Protein identification was also performed by mass spectrometry, through 
gel digestion protocol, as described in the methods. The mass 
spectrometry data confirmed the protein identity, allowing their 
confident use in the interaction and structural experiments. 
  
 
Chapter 4 | Surface Plasmon Resonance 
 - 60 - 
Chapter 4 – Surface Plasmon Resonance 
 
4.1: “Yes/No” Binding Experiment 
 
Surface plasmon resonance was the first method used in the 
investigation of eIF4E4/PABP1 protein-protein interactions. The first 
strategy used was the initial screening of PABP1 domains against 
eIF4E4(iv). This initial screening used eIF4E4(iv) immobilized on a CM5 
chip, through amine coupling (as described in the Materials and 
Methods).  This experiment was conducted in a 2-1, 4-3 mode (Figure 32) 
i.e. cells 1 and 3 were used as reference, while cells 2 and 4 were used in 
target immobilization, in such way that the reference data was 
subtracted from the target/ligand data. A range of different ligands are 
then screened, verifying which among them bind to the immobilized 
target protein (Figure 32).  
 
Figure 32: (A) Flow cell modes used in the Yes/No binding experiments; (B) schematic of 
the Yes/No binding screening experiment. 
 
This kind of experiment is very useful in assessing which members of a 
varied group of ligands (in this case, PABP1 domains) binds to a target 
(eIF4E4(iv). The immobilization strategy, amine coupling, is very simple, 
allowing the immobilization of protein to a chip surface; however, there 
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is a drawback in this approach, since it binds the target protein in an 
isotropic manner, which can restrict the availability of the potential 
binding domain. Therefore, this strategy is very useful for qualitative 
screening, and provides a good means of detecting binding per se, 
although not with the highest precision.  
 
At this first stage, we were interested in identifying the PABP1 regions 
that would bind to eIF4E4(iv), so a Yes/No binding experiment with an 
amine coupling immobilization was an adequate technique. We chose a 
number of PABP1 domains, as follows: full length PABP1, A, B, C, D, F, G, I, 
J (Figure 33) and used BSA and running buffer as negative controls; while 
immobilizing eIF4E4(iv) on the chip surface. Some of the domains gave 
low production yields, preventing additional purification by size 
exclusion chromatography.   
 
 
Figure 33: PABP1 domains used for Yes/No binding experiments. 
 
The results obtained in this experiment are displayed in Figure 34: 
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Figure 34: Yes/No binding sensorgram of PABP1 domains against eIF4E4(iv). 
 
 
Due to the qualitative nature of this experiment, it was performed using 
the highest concentration available for each of the proteins (please see 
table in Annexes) in order to maximize the observation of binding to 
eIF4E4(iv). eIF4E4(iv) was immobilized by amine coupling to a 
concentration of 1000 units, and then screened against the PABP1 
proteins. 
 
The data displayed in the sensorgram indicates binding for full length 
PABP1 and for its C-terminal domains, C, G and J. Surprisingly, it also 
indicated that one N-terminal domain, A, also binds to eIF4E4(iv). The 
binding of full length PABP1, and especially its C-terminal domains 
supports the hypothesis of PABP1/eIF4E4 interaction. The negative 
controls, BSA and running buffer did not show any binding. 
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It was noted that the curves showed limited dissociation, which could 
have indicated the occurrence of very strong binding (tight binding with 
very low dissociation), or a contribution of unspecific binding. In order to 
further investigate these interactions, binding affinity experiments were 
then performed.  
4.2: Binding Affinity Experiments 
 
Binding affinity experiments, differently from the Yes/No binding 
detection approach, use a single ligand, at varied concentrations, to 
evaluate its affinity towards a target. In these experiments, a target (in 
this case eIF4E4(iv)) is also immobilized on a chip surface, and different 
ligand concentrations are tested in duplicates. We tested several PABP1 
domains, and the most relevant results are shown in this chapter (further 
data are available in the Annexes).  
 
Figure 35: Binding affinity sensorgrams of eIF4E4(iv) against: (A) PABP1 full length; (B) 
PABP1(C); (C) PABP1(G); (D) PABP1(J). 
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The binding affinity experiments showed results that agreed with the 
Yes/No binding experiments. The sensorgrams suggested the occurrence 
of binding, however, there was a lack of significant dissociation in the 
sensorgrams, feature that must be considered for KD calculations. 
There are two main methods to calculate affinity using SPR, the kinetic 
method and the thermodynamic method. Considering a two components 
system, protein/ligand, in equilibrium the following equations applies: 
 [𝑃] + [𝐿] ⇌ [𝑃𝐿] and [()][(][)] 	= ,-,. = 𝐾0 
And therefore: 𝐾1 = 123∴ 𝐾1 = ,.,- 
Where KA is the association constant, KD is the dissociation constant, kd 
dissociation rate constant and ka the association rate constant.  
Considering the equations above, it is possible to observe that by 
evaluating the association and dissociation rates in a sensorgram, it is 
possible to calculate affinity, by fitting data into the curves. 
 
 
Figure 36:  Example of a SPR curve, with ligand association phase highlighted by the 
blue line, and the dissociation phase highlighted in red. 
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The other method, thermodynamic, considers the equipment response to 
a determined ligand concentration, and for instance, KD is equivalent to 
the ligand concentration that has a response of half of the maximum 
response (Rmax) obtained in a measurement (KD is [L] whose response is 
Rmax/2). 
 
       (A)     (B) 
 
Figure 37: (A) example of SPR curves in experiment to obtain affinity values; (B) KD 
calculation using data extracted from SPR curves. 
 
 
The kinetic strategy for calculating KD is not appropriate for the SPR 
dataset obtained in the ‘Yes/No experiments, since the conditions for 
dissociation had not been optimised.  
 
The KD calculation using the thermodynamic approach, however, can be 
performed using only the association segment of an SPR curve. Table 3 
display the KD values obtained for the most relevant proteins tested (data 
regarding the remaining domains are in the Annexes). These should only 
be taken as indicative values. 
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Table 3: KD calculations of some of the tested proteins. 
Ligand Calculate KD/µM 
PABP1 0.3 
PABP1(A) 1.1 
PABP1(C) 0.4 
PABP1(G) 0.4 
PABP1(J) 0.8 
 
The data obtained suggest that the affinity between eIF4E4(iv) and PABP1 
is in the low µM range. However, the unusual behaviour regarding protein 
dissociation suggest that complementary KD calculations using 
alternative techniques may be required to increase confidence in these 
results. 
 
Similar experiments were also performed, using eIF4E4(iv)-SBP 
constructs and SA chips (streptavidin coated chip, that allows, for 
example, the immobilization of SBP-tagged proteins, where SBP stands 
for Streptavidin Binding Protein), but it was not possible to immobilize 
the protein to satisfactory levels.  
NTA chips (Nitrilotriacetic acid coated chips, that allow the 
immobilization of His-tagged proteins) were also attempted, but the 
ligand (in this case, eIF4E4(iv)-SBP) displayed a significant unspecific 
binding to the chip surface (including in the blank, control channels), 
preventing the use of this strategy. 
 
More detailed investigations were subsequently undertaken to optimise 
the conditions for SPR in the case of eIF4E4(iv) vs PABP1. For this, the 
flow rate was increased to 60µL/min, and temperature set to 30˚C. 
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Figure 38:  Binding affinity sensorgram of eIF4E4(iv) against PABP1 full length, under 
optimized conditions.  
 
The results revealed that it is possible to achieve a more balanced 
association and dissociation curves (Figure 38). However, the initial SPR 
experiments had served their purpose in that they provided a guide to the 
locations of key binding sites, and attention now turned to the utilization 
of a parallel technique. 
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Chapter 5 – Microscale Thermophoresis 
 
5.1: Binding Affinity Experiments 
 
MST binding experiments use a fluorescent-tagged target molecule and 
a ligand. For this, the target molecule has its concentration constant, 
while the ligand is tested in various concentrations (typically 16 different 
concentrations [L]1 to [L]16, in a standard MST run). Glass capillaries are 
filled with target molecule/ligand solutions, and then undergo MST 
analysis. 
 
Figure 39: MST sample preparation, the target molecule concentration is kept constant, 
while the ligand concentration, [L], is varied, with [L]1 > [L]2 > …>[L]16. 
 
MST experiments rely on the thermal diffusion of a complex. Before 
thermophoresis starts (initial state), the molecules as distributed 
randomly in the bulk of the solution contained in the capillaries. When 
an IR laser is turned on, a temperature gradient builds up in the solution, 
and typically, molecules move away from the laser focusing point 
(although it is also possible that molecules move towards the 
temperature gradient, in a process known as negative thermophoresis). 
Since the target protein is fluorescent, their local concentration near the 
temperature gradient is reduced, and this leads to a decrease in the 
fluorescence signal measured at this spot. When the IR laser is turned off, 
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the temperature gradient dissipates, and the molecules then can return 
to the initial area. Since the mass of a molecule affects its mobility in the 
temperature gradient, there is a difference between the free target 
molecule mobility and the target/ligand complex mobility. This variation 
in motion is used in MST measurements to calculate affinity, since the 
different ratios of target/ligand contained in the capillaries allow the 
calculation of affinity curves.    
 
 
 
Figure 40: Microscale thermophoresis schematic (based on Jerabek-Willemsen, 2014). 
There are four main stages during the MST measurement, 1: Initial state; 2: Diffusion; 3: 
Steady state and 4: Back-diffusion. The effect of this stages is reflected in the 
fluorescence intensity over time, as observed in a typical MST curve.  
 
 
In this study, PABP1 domains were tested (at least in duplicates) against 
eIF4E4(iv), the fluorescent-labelled target protein; their relative affinities 
are shown in Figure 41. 
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The MST data show a higher affinity for PABP1 C-terminal domains 
(PABP1(C), PABP1(G) and PABP1(J)), and for full-length PABP1. PABP1(A) 
shows weak binding, significantly smaller than observed for the full-
length protein and the C-terminal domains. These results suggest that 
the C-terminal region of PABP1 is involved in binding with eIF4E4. 
 
 
Figure 42: PABP1 full length and C-terminal domains with higher affinities for 
eIF4E4(iv). 
 
Figure 41: Relative affinity of PABP1 domains against eIF4E4(iv).  
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In order to further investigate the importance of PABP1 C-terminal in 
binding to eIF4E4(iv), we used deletion constructs, where different parts 
from PABP1 C-terminal domains were removed (Figure 43 illustrates 
these deletion domains). 
 
Figure 43: Representation of PABP1 C-terminal deletion constructs. 
 
We expected that if the PABP1 C-terminal region interacts with 
eIF4E4(iv), no binding curve would be observed, giving additional 
evidence that PABP1 C-terminal is involved in binding with eIF4E4. 
 
 
 
Figure 44:  Microscale thermophoresis affinity 
plots of: (A) PABP1(C); (B) PABP1(J); (C) PABP1(G); 
(D) PABP1 full length; (E) PABP1(ΔC);  
(F) PABP1(ΔJ) and (G) BSA (negative control). 
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The affinity values obtained for the PABP1 C-terminal domains were in 
the nM range, and a summary of the obtained values are found on Table 
4. 
Table 4:  PABP1 domains/eIF4E4(iv) KD calculations by Microscale Thermophoresis. 
Protein KD / nM Protein KD / nM 
PABP1(A) 226 PABP1(L) 891 
PABP1(B) 659 PABP1(M) 5860 
PABP1(C) 40 PABP1(N) 1020 
PABP1(D) 900 PABP1(O) 2800 
PABP1(F) No binding PABP1 FL 50 
PABP1(G) 17 PABP1(ΔC) No binding 
PABP1(I) No binding PABP1(ΔC) No binding 
PABP1(J) 21 BSA No binding 
 
The MST data also allow the estimation of the stoichiometry involved in 
eIF4E4/PABP1 binding, through the calculation of Hill coefficients. The 
data fitting to the Hill Equation (GOUTELLE, 2008) (using a Logistic non-
linear curve fit) revealed a Hill Coefficient close to 1 (Table 5), suggesting 
a noncooperative, independent binding mode. 
 
Table 5: Hill coefficient for the C-terminal domains of PABP1, when binding to eIF4E4(iv). 
Target Ligand Hill Coefficient 
eIF4E4(iv) Full length PABP1 0.85 
eIF4E4(iv) PABP1(C) 0.84 
eIF4E4(iv) PABP1(G) 1.08 
eIF4E4(iv) PABP1(J) 0.95 
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These data suggest that the binding ratio between eIF4E4(iv) and PABP1 
is 1:1, in such way that the data indicate that only one molecule of each 
protein is required for the complex formation. 
The MST experiments pass through a number of quality checks that 
verify several parameters that are used to assess the measurement 
reliability. For example, it is important to verify for deformities of the 
capillaries (what would lead to faulty measurements). This is achieved by 
measuring the fluorescence intensity along length of the capillaries 
inside the inside the equipment; good, well-shaped capillaries display a 
Gaussian shaped fluorescence curve symmetrically centered on the 
capillary axis. Capillary evaluation also provides information regarding 
the occurrence of protein adsorption inside the capillary wall (affecting 
measurement accuracy, since adsorption of the target fluorescent-
tagged protein leads to fluorescence intensity inhomogeneity). The 
occurrence of adsorption is identified by the occurrence of “split” peak on 
the capillary peak format, and it is verified at the start and end of each 
measurement. 
 
Figure 45: (A) Capillaries shape quality check; (B) capillary without protein adsorption; 
(C) capillary with protein adsorption, with higher degree of adsorption observed at the 
end of measurement. 
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The presence of aggregated protein can also affect the accuracy of MST 
measurements. An ideal MST measurement displays smooth curves that 
follow the typical thermophoretic profile; however, if protein aggregates 
are present, these curves show bumps and a chaotic behaviour, deviating 
from the typical profile. 
 
Figure 46: (A) MST curves of an aggregate-free sample, displaying smooth curve; (B) MST 
curves of an aggregate-containing sample, displaying bumps and erratic behaviour. 
 
Another important parameter that needs to be evaluated is the 
occurrence of ligand-induced photobleaching. The MST experiment 
measures fluorescence intensity in two moments during 
thermophoresis; the initial measurement during the “cold” stage (show by 
the blue bars in Figure 47), and the second measurement during the “hot” 
stage (show by the red bars in Figure 47). The fluorescence levels during 
the “cold” stage must be similar along the different capillaries (and 
therefore in the different ligand concentrations). Variations in this stage 
indicate that the ligand is inducing fluorescent-tagged target 
photobleaching, and although the data obtained can provide qualitative 
data (i.e. the occurrence or not of binding), the accurate calculation of 
affinity constants is difficult. 
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Figure 47: (A) MST curves without the occurrence of ligand induced photobleaching, 
observed by constant fluorescence levels in the blue bar area; (B) MST curves with the 
occurrence of ligand induced photobleaching, observed by varied fluorescence levels in 
the blue bar area. 
 
The implementation of quality checks on different measurement 
parameters give greater confidence in the data obtained by MST.  
 
Supplementary to the eIF4E4/PABP1 studies, the interactions of these 
proteins with eIF4G3 were also investigated. There are a few previous 
reports in the literature (DA COSTA LIMA, 2010; FREIRE, 2017) describing 
the interaction between PABP1 and eIF4G3. However, this interaction is 
described as being very weak, or even non-existent (FREIRE, 2017; DE 
MELO NETO, 2015), thus leaving uncertainty as to whether these two 
proteins really bind to each other. For this reason, another eIF4E4 
derivative construct was prepared, eIF4E4(v) (Figure 48).   
 
 
 
Figure 48: eIF4E4 full length and sectors eIF4E4(iv) and eIF4E4(v). 
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eIF4E4(v) is a longer construct, composed by the whole eIF4E4(iv), and 
extends until the eIF4E4 C-terminal. eIF4E4(v) was designed to have this 
architecture in order to contain both the PAM2 motif, responsible for 
PABP1 binding, as described in this work, but also eIF4G3 domains, 
described to be located within the eIF4E4 signature domain (FREIRE, 
2017).  
It was not possible to obtain eIF4E4(v) as an isolated protein, but its 
production as a co-expressed complex with PABP1(J) was successful 
(complex prepared by Dr Maja Firczuk). 
This investigation involved the MST analysis of eIF4G3 with eIF4E4(iv), 
PABP1, PABP1(J) and the complex {eIF4E4(v)/PABP1(J)}. 
 
 
Figure 49: MST data of eIF4G3 and (A) eIF4E4(iv); (B) PABP1 FL; (C) PABP1(J) and (D) 
{eIF4E4(v)/PABP1(J)}. 
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The titration of eIF4G3 with eIF4E4(iv), PABP1 and PABP1(J) did not reveal 
evidence of binding. The absence of binding for eIF4E4(iv) was expected, 
since this construct does not contain the region responsible for eIF4G4 
binding, located in the eIF4E4 signature domain (FREIRE, 2017). 
The titration of eIF4G3 with PABP1 and PABP1(J) was not able to detect 
binding between these proteins. These data also suggest that there might 
be no binding between eIF4G3 and PABP1 in trypanosomatids, or that the 
interaction is very weak. 
 
The titration of eIF4G3 with eIF4E4(v)/PABP1(J) complex, however, 
detected binding between the proteins (Figure 49).  
 
It is important to highlight that although it was possible to detect binding 
between eIF4G3 and eIF4E4(v)/PABP1(J), this three-components complex 
was not very stable, with the rate of aggregation increasing with time. 
This might indicate that additional factors may be necessary to stabilize 
the whole complex, and therefore, further studies will be necessary. 
 
The set of results obtained for eIF4G3 and eIF4E4(iv), PABP1(J), PABP1 and 
eIF4E4(v)/PABP1(J) complex suggest that, in the trypanosomatid 
translation initiation complex, the interaction between eIF4G3 and 
PABP1 is very weak or absent. This behaviour suggests the hypothesis 
that the extended eIF4E4 N-terminal might be responsible for the 
“scaffolding” of the eIF4G3-eIF4E4-PABP1 complex, in such way that it 
replaces the eIF4G3/PABP1 interaction. 
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Chapter 6 – NMR and Crystallographic analysis of 
the PABP1 PAM2 domain  
 
6.1: Nuclear Magnetic Resonance - NMR 
 
The NMR experiments provided information regarding the binding 
interactions between Leishmania eIF4E4(iv) and PABP1(J).  
 
The initial NMR experiments were used to obtain qualitative information 
regarding protein folding, through the observation of spectral 
characteristics in the 1H spectra.  
 
Figure 50 shows the proton spectra of the PABP1(J). There are two major 
areas of interest, the first being in the 9-6 ppm region (left-hand side of 
the spectrum, in the dashed box), and the second located in the 1-0 ppm 
region (right-hand side of the spectrum, in the dashed box). 
 
Folded proteins tend to have sharp, well defined and dispersed peaks 
(PAGE, 2005) in the 9-6 ppm region (amide and aromatic region) and 
intense, sharp peaks in the 1-0 ppm region (methyl group region (PAGE, 
2005)). Observing PABP1(J) domain spectrum, it is possible to clearly see 
these characteristics, giving a good qualitative evidence that the protein 
is well folded. 
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Figure 50: PABP1(J) proton spectrum, with characteristic aspects of a folded protein. 
 
In contrast, Figure 51 shows the proton spectrum for eIF4E4(iv), where the 
opposite situation is observed, when compared with the PABP1(J) 
domain. The 9-6 ppm region is poorly spread, with non-sharp peaks, and 
the typical methyl peaks in the 0-1 ppm region can barely be seen. These 
conditions suggest that eIF4E4(iv) is significantly unstructured, result 
that agree to the expected lack of significant structure for eIF4E4(iv), 
since this protein is rich in prolines (that commonly contribute to 
destabilization protein structures). 
 
Figure 51: eIF4E4(iv) proton spectrum, with characteristic aspects of an unfolded protein. 
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NMR techniques were used to verify binding between Leishmania 
eIF4E4(iv) and PABP1(J), and if binding is detected, identify the 
regions/motifs involved in binding. We used bidimensional experiments, 
{1H-15N}-HSQC, where each peak corresponds to an amino acid residue. 
 
We have done titrations with eIF4E4(iv) and PABP1(J), initially titrating 
isotopically labelled eIF4E4(iv) with unlabelled PABP1(J), and then, used 
isotopically labelled PABP1(J), that was then titrated with unlabelled 
eIF4E4(iv). 
 
The PABP1(J) spectrum was obtained in good resolution, with peaks well 
resolved and dispersed along both dimensions. The peaks spread is an 
indication of protein folding (in a similar way as described above for the 
proton spectra).  
 
Amino acid residues assignment was performed using triple resonance 
experiments, as described in the Material and Methods. The peaks were 
identified and assigned, and this information was used in the 
identification of the binding motif, after the titration experiments.  
The HSQC NMR spectrum of the titration of isotopically labelled PABP1(J) 
with unlabelled eIF4E4(iv) is shown below:  
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Figure 52: HSQC spectra of PABP1(J) Domain before (in blue) and after (in red) the 
titration with eIF4E4(iv). The residues that had alterations in their peaks, indicating 
binding, are highlighted by dashed circles. 
 
After eIF4E4(iv) was added to PABP1(J), a number of peaks had their 
intensities dramatically reduced (this is observed when the interactions 
are in a range between slow (tight binding) and fast exchange (weaker 
binding) (WILLIAMSON, 2013)).  
This behaviour is a strong indication that binding occurs between the two 
proteins. The residues identified as involved in binding are highlighted 
in PABP1(J) sequence below: 
 
482       
LPPITPQELESMSPQEQRAALGDRLFLKVYEIAPELAPKITGMFLEMKPKEAYELL 
                    560 
NDQKRLEERVTEALCVLKAHQTA  
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The mapped residues that the experiments suggest being involved in 
binding comprise the sequence with high homology to the MLLE domain, 
through the sequence KITGMFLE. This motif, along with its partner will 
be discussed in more detail in the following chapter. 
The next step was to repeat the experiment, in reversed order, using 
isotopically labelled eIF4E4(iv), and then titrating with unlabelled 
PABP1(J). The eIF4E4(iv) spectrum was also obtained in good resolution, 
with peak well resolved, but displaying smaller dispersion along 1H and 
15N dimensions. The concentration of peaks is a characteristic of 
unfolded protein, agreeing to what was described for the correspondent 
proton spectra. The HSQC NMR spectrum of the titration of isotopically 
labelled eIF4E4(iv) with unlabelled PABP1(J) is shown below:  
 
 
Figure 53: HSQC spectra of eIF4E4(iv) before (in blue) and after (in red) the titration with 
PABP1(iv). The residues that had alterations in their peaks, indicating binding, are 
highlighted by dashed circles. 
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After eIF4E4(iv) was titrated with PABP1(J), peaks also had their 
intensities reduced, disappearing in a similar way as observed in the 
PABP1(J) experiment. Again, the behaviour is an indication of binding is 
between the two proteins. The residues identified in the experiment are 
highlighted in eIF4E4(iv) sequence below: 
 
140        
MNPNATEFMPGRRNGPDGGLEALPTSTADMELAKTPAGAAAAAVHAPSLPGAVRRS 
                            225 
LQNSPIIQPSRLSVKSASEIEAISKNSALNA 
 
 
The mapped residues suggested to be involved in binding are 
correspondent to PAM2 motifs, that are known to bind MLLE domain, 
through the sequence (L/P/F)x(P/V)xAxx(F/W)xP. This motif, along with 
MLLE domain will be discussed in more detail in the following chapter. 
In order to confirm the binding motif, small peptides were synthesized, 
corresponding to the region that is suspected to be involved in binding.  
 
The peptides were synthesized by our collaborators in the University of 
Leeds, in the group of Prof. Andrew Wilson. In this new set of 
experiments, we performed titrations in a way similar to the one used 
with the protein pairs, but now isotopically labelled PABP1(J) was titrated 
with unlabelled eIF4E4(iv) peptide, also called PAM2 peptide (Ac-
HHMNPNATEFMPGR-NH2).   
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Figure 54: HSQC spectra of PABP1(J) Domain before (in blue) and after (in red) the 
titration with eIF4E4(iv) peptide. The residues that had alterations in their peaks, 
indicating binding, are highlighted by dashed circles. 
 
After the peptide was added to PABP1(J), it was observed that the peaks 
that have disappeared were the same peaks that had disappeared in the 
experiment where PABP1(J) was titrated with eIF4E4(iv). This result gave 
greater confidence in the indication that binding occurs between the two 
proteins. The peptide experiment not only confirmed the existence of 
binding between eIF4E4(iv) and PABP1(J), but also strengthened the 
hypothesis that the PAM2 motif in eIF4E4(iv) is involved in binding. The 
realization of an experiment involving labelled eIF4E4(iv) and a PABP1(J) 
peptide would not be feasible, since the peptide that would contain the 
whole binding motif would be very large and challenging to be 
synthesized (the peptide would have almost the same length of that 
PABP1(J)).  
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6.2: Crystallographic data 
 
Crystallographic experiments were also attempted in order to obtain 
more information regarding eIF4E4(iv)/PABP1(J) binding. These 
experiments were performed by Dr Maja Firczuk, from McCarthy’s group, 
in collaboration with Prof. Alex Cameron group, also from the School of 
Life Sciences of the University of Warwick. 
 
The crystallization experiments were successful in obtaining high 
resolution crystals of PABP1(J), as shown in Figure 55. In this section, I 
will analyze the crystallographic data, and then combine it with NMR 
results. 
 
 
 
 
 
 
 
 
Figure 55: PABP1(J) crystal structure, with 5 𝛼-
helices assigned. 
 
 
 
 
 
 
Figure 56: PABP1(J) 𝛼-helices location within its primary sequence. 
 
The PABP1(J) crystal structure reveals the typical structure for PABC 
domains that contain MLLE region (XIE, 2014), composed by five 
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consecutive 𝛼-helices. PABP1(J) dimensions are x=26.5Å, y=28.5Å and 
z=46.0Å, and a summary of some of PABP1(J) structural properties is 
presented in Table 6: 
 
Table 6: PABP1(J) structural properties obtained by crystallography. 
Helix length/Å   Angle between consecutive helices/o 𝛼1 8.9  𝛼2 𝛼3 𝛼4 𝛼5 
𝛼2 26.0 𝛼1 138.98    𝛼3 14.6 𝛼2  139.59   𝛼4 12.8 𝛼3   132.26  𝛼5 24.5 𝛼4    117.45 
 
In order to obtain additional details for binding motif mapping, the NMR 
data was combined with PABP1(J) crystal structure, highlighting the 
residues (in blue) that had their signals abolished in the NMR data (Figure 
57).  
 
 
 
 
 
 
 
Figure 57: PABP1(J) crystal structure, with 
binding residues identified by NMR 
highlighted in blue. 
 
 
 
 
The binding residues identified by the NMR experiments are located in 
the 𝛼-helices 𝛼2, 𝛼3 (majority) and 𝛼5. The comparison of the residues 
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identified shows a remarkable similarity with data from the literature 
(XIE, 2014), as displayed in Figure 58:  
(A)      (B)
     
Figure 58: (A) PABP1(J) crystal structure with binding motif highlighted in blue; (B) 
human PABC1 MLLE domain, with binding residues in red, as described in the literature 
(XIE, 2014).  
 
Additionally, a crystal structure of a complex of PABP1(J) and the peptide 
that contains the eIF4E4(iv) PAM2 binding motif was obtained (Figure 59). 
The amino acid residues from the peptide are positioned in such way that 
they interact in the MLLE domain in PABP1(J), agreeing with the NMR 
data. 
 
 
 
Figure 59: PABP1(J) crystal structure, with 
binding residues identified by NMR 
highlighted in blue and PAM2 peptide in 
orange sticks/green mesh. 
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In order to better display the interaction partners (i.e. amino acid residues 
that interact with each other), a map was prepared, as shown in Figure 
60. 
 
Figure 60: PABP1(J) and eIF4E4(iv) peptide interaction map, with eiF4E4(iv) peptide 
residues represented on the top (blue); PABP1(J) residues on the bottom (red). 
Interactions are indicated by the green dashed lines. 
 
In order to obtain a comprehensive biophysical evaluation of these 
bindings, electrostatic and hydrophobicity maps were prepared.  
(A) (B) 
Figure 61: Electrostatic mapping of (A) PABP1(J) and (B) eIF4E4(iv) peptide. 
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The electrostatic map (Figure 61) does not suggest that the binding 
between PABP1(J) and eIF4E4(iv) takes place via electrical attraction, 
since there is no clear indication that this type of interaction is occurring 
in this protein/ligand complex. However, the evaluation of the 
hydrophobicity maps offers an alternative explanation regarding the 
nature of binding, as displayed in Figure 62. 
(A)      (B) 
 
 
(C) 
Figure 62: Hydrophobicity mapping of (A) PABP1(J) M140 pocket, (B) PABP1(J) F147 
pocket, and (C) eIF4E4(iv) peptide. 
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The hydrophobicity map reveals multiple points of interaction based on 
hydrophobicity between PABP1(J) and eIF4E4(iv). It is important to 
highlight the eIF4E4(iv) residues M140 and F147, both very hydrophobic. 
These two residues are located within two hydrophobic pockets, known 
to be involved in PABC binding to several ligands (XIE, 2014; KOZLOV, 
2010).   
More detailed information can be found in the Annexes Chapter. 
6.3: PAM2 motifs 
 
We also investigated the presence of PAM2 motifs and MLLE domains in 
the other eIF4E and PABP1 isoforms of L. major.  
Among the eIF4E isoforms, only eIF4E3 would contain an amino acid 
sequence that reasonably matches a PAM2 motif, but with significant 
difference from the PAM2 sequence observed in eIF4E4. The remaining 
eIF4E isoforms are significantly shorter than eIF4E4, not containing an 
equivalent N-terminal amino acid sequence.   
                  121                                        168 
L. major eIF4E1    ------------------------------------------------ 
L. major eIF4E2    ------------------------------------------------ 
L. major eIF4E3    AA----AVAKPPSTQPATKLSAAAEPFVPGGPKQMSATSTHVDPKATTE 
L. major eIF4E4    VAARSVPTRFSPATVPRHHMNPNATEFMPGRRNGPDGGLEA-LPTSTAD 
L. major eIF4E5    ------------------------------------------------ 
L. major eIF4E6    ------------------------------------------------ 
 
 
The three PABP1 isoforms have the MLLE domain in their primary 
structure. However, the (Là F) substitution is only present in PABP1, 
while PABP2 and PABP3 display the standard MLLE sequence. It is also 
important to note that the KITG sequence that precedes the MLLE/MFLE 
is also conserved in the other PABP1 isoforms, while the remaining 
PABP1 residues that are involved in binding in with eIF4E4 are only 
marginally conserved in the other isoforms. 
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                    519                                    560 
L. major PABP1      PKITGMFLEMKPKEAYELLNDQKRLEERVTEALCVLKAHQTA 
L. major PABP2      AKITGMLLEMDNAEILNMLDSPTMLDSKIAEAQDVLNRHMSV 
L. major PABP3      AKITGMLLEMSREEIFEILADHFALLSKIQEANAVLQQHTGN 
 
 
The PAM2 motif in Leishmania’s eIF4E4 is not present in human eIF4E. 
However, the PABP1 MLLE domain is present in both species, with 
Leishmania PABP1 having an amino acid substitution (LàF) when 
compared to the standard MLLE motif (MLLE à MFLE). 
 
                          119                                  158 
Leish major eIF4E4     PAVAARSVPTRFSPATVPRHHMNPNATEFMPGRRNGPDGG 
Homo sapiens eIF4E4    ---------------------------------------- 
 
                          520                                  560 
Leishmania major PABP1    KITGMFLEMKPKEAYELLNDQKRLEERVTEALCVLKAHQT 
Homo sapiens PABP1        KITGMLLEIDNSELLHMLESPESLRSKVDEAVAVLQAHQA 
 
 
 
In order to investigate if the PAM2/MLLE interaction might be present in 
other trypanosomatids, a number of species were chosen, and their 
eIF4E4 and PABP1 sequence aligned. The relevant section of these 
alignments is presented below. 
 
eIF4E4 
                         119                                  154 
Leishmania major         PAVAARSVPTRFSPATVP----RHHMNPNATEFMPGRRNG 
Leishmania panamensis    -------------------------MSPNATEFVPGRSNG 
Leishmania guyanensis    PAVAARSVPTRFSPATVP----R-HMSPNATEFVPGRSNG 
Leishmania braziliensis  PAVAARSVPTRFSPATVP----R-HMNPNATEFVPGRSNG 
Leishmania mexicana      -------------------------MNPNATEFMPGRRNG 
Leishmania infantum      -------------------------MNPNATEFMPGRRNG 
Trypanosoma brucei       -PVSTHVIPTRMSPVHAPS--AAFHMSPNAVSYVPRGA-- 
Trypanosoma theileri     -PTAALRFPTRMSPMHAPFPPVSSTMNPDAKDFIPHLS-- 
Trypanosoma cruzi Brener -PTTALRLPTRMSPMHAPFPSVSISMNPNATDFVPHLT-- 
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PABP1 
                           520                                   560 
Leishmania major           KITGMFLEMKPKEAYELLNDQKRLEERVTEALCVLKAHQTA 
Leishmania panamensis      KITGMFLEMNPKEAYELLNDQKRLEERVTEALCVLKAHQTV   
Leishmania guyanensis      KITGMFLEMNPKEAYELLNDQKRLEERVTEALCVLKAHQTA 
Leishmania braziliensis    KITGMFLEMNPKEAYELLNDQKRLEERVTEALCVLKAHQTV   
Leishmania mexicana        KITGMFLEMKPKEAYELLNDQKRLEDRVTEALCVLKAHQTT   
Leishmania infantum        KITGMFLEMKPKEAYELLNDQKRLEERVTEALCVLKAHQTA   
 
Trypanosoma brucei         KITGMFLEMNPKEALALLSNPKLMHEKVTEALCVLKVHASS  
Trypanosoma theileri       KITGMFLEMDLKEAFTLLYNQKLLHEKVTEALCVLKAHGTT  
Trypanosoma cruzi Brener   KITGMFLEMDLKEAFTLLTNQRLLQEKVIEALCVLKAHEST 
 
 
Both the PAM2 motif and MLLE domain are very conserved in 
trypanosomatids, suggesting an analogous assembly of translation 
initiation factors across the species, at least regarding the eIF4E4/PABP1 
interaction. It is also notable that not only the MLLE domain is conserved, 
but also the (LàF) substitution in the various trypanosomatid species. 
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Chapter 7 – Discussion 
 
Leishmaniasis is an important disease that affects a large number of 
people and, as explained in the Introduction, the identification of 
potential new therapeutic targets is therefore very important. 
 
The trypanosomatid translation initiation complex displays 
characteristics that are not observed elsewhere, making it a very 
interesting object of study. The trypanosomatid translation initiation 
factor eIF4E4 has a unique N-terminal sequence whose interaction with 
PABP1 has not previously been described at the molecular level. The fact 
that this interaction is not observed in other eukaryotes makes it an 
interesting potential target for new therapeutic approaches. 
 
The research described in this thesis demonstrates that synthetic 
peptides can form tight complexes with the trypanosomatid translation 
factors (eIF4E4 and eIF4G3). This demonstrates the potential value of 
peptides or peptidomimetics as drug discovery tools. By determining the 
molecular architecture of the complexes formed by these factors, we 
have a source of information that could, in future, inform the design of 
peptide-based inhibitors. One way of approaching this would be to screen 
peptide derivatives that mimic protein interaction sites in quantitative 
assays – for example, plate-reader assays utilizing, in each case, a 
fluorescein-derivatized peptide copy of one of the interaction 
sequences/domains in a binding pair, thus maximizing the change in 
anisotropy measured upon complex formation by the binding partners. It 
will be possible to test peptides of different lengths so as to establish a 
range of affinities for competition assays to be used in screening.  
 
Chapter 7 | Discussion 
 - 94 - 
Using this proof-of-concept platform, it will then be possible to explore a 
range of modified synthetic peptides with additional properties (e.g. 
membrane-permeating and/or proteolysis-resistant) that are expected to 
be advantageous in the in vivo context. Peptidomimetics are useful drug 
discovery tools with high structural diversity that can be used to test 
target validity and, in cases like this, to explore the structure of relevant 
intermolecular interfaces. Bioinformatic analysis coupled to modelling of 
intermolecular docking and experimental structural interaction studies 
would also be used to refine the design of peptidomimetic derivatives of 
binding-domain amino acid sequences. One promising approach here 
would be the implementation of peptide stapling to lock peptides into 
conformations that have a high affinity for the target-binding domain. 
Stapling (SCHAFMEISTER,2000; VERDINE, 2012) is an effective helix-
stabilizing method and can be used to build additional functionality into 
the peptide, including increased hydrophobicity, conferring membrane-
permeability (ZHANG, 2008). The potential value of this would be that 
peptidomimetics might be developed that can enter into living cells. 
This strategy has been used previously to design and synthesize eIF4E-
binding peptidomimetics based on the binding-domain sequences of 
human 4E-BP1 and eIF4G (TAIT, 2010). Of course, in the present case, the 
objective would be to develop peptidomimetics that inhibit protein-
protein interactions in Leishmania, but not in the human translation 
machinery. 
Another strategy for developing potential anti-Leishmania drugs would 
be to screen for small-molecule inhibitors. At least one effective small 
molecule competitive inhibitor (called 4EGI-1) has previously been 
identified that targets the human eIF4E-eIF4G interaction (identified 
from the Chembridge DiverSet E Library (MOERKE, 2007)). Screening 
could again be based on fluorescence anisotropy assays as described 
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above. In parallel, the small molecule ‘ligandability’ of potential drug 
targets can be tested via NMR-based fragment screening (EDFELDT, 2011). 
Once small molecule inhibitory leads have been identified that 
specifically target Leishmania protein-protein interactions within 
promastigotes or amastigotes, molecular modelling work can be used to 
pursue a refine and re-test cycle in order to optimise the inhibitory 
properties of the selected ligands.  
As with the peptidomimetics, the small molecule inhibitors will be tested 
in both in vitro and in vivo assays. As the number of structurally analysed 
protein-protein interactions increases, the breadth of potential inhibitor 
molecules will be expanded, thus increasing the likelihood of finding at 
least one inhibitor that might form the basis of proper drug development. 
 
Trypanosomatids have multiple isoforms for some of its translation 
initiation factors (e.g. it has 6 eIF4E, 5 eIF4G and 3 PABP isoforms). The 
existence of such a high number of isoforms is likely to be related 
to Leishmania’s adaptation to its complex life cycle, in which it is 
exposed to different host environments. For example, eIF4E1 is found at 
significantly higher levels in amastigotes, and seems to be involved in 
the amastigote phase of the parasite (YOFFE, 2006), when it lives inside 
the mammalian host, and faces higher temperatures. The expression 
levels of the other eIF4E isoforms, however, do not seem to be 
significantly affected by temperature variations. eIF4E5 and eIF4E6 
(FREIRE, 2011), on the other hand, are involved in cell motility during the 
promastigote phase. 
  
In this study, several methods were used in order to investigate the 
interactions between Leishmania’s eIF4E4 and PABP1 proteins. The 
overproduction of the full-length versions of these proteins was found to 
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be difficult. A number of strategies were explored in attempts to obtain 
these proteins, via the use of different tags (His-tag, GST, MBP, among 
others), and several cultivation conditions. The production and 
purification of PABP1 was successful, although at moderate yield, while 
little progress was achieved with the other full-length proteins. 
 
Full-length eIF4E4 could not be obtained in soluble form on its own. 
However, it was found possible to generate it in E. coli as part of a complex 
with PABP1. The literature (ZINOVIEV, 2011) has previously provided 
qualitative evidence of an analogous interaction between these two 
proteins in L. amazonensis on the basis of pull-down data.  
In order to map accurately the potential binding regions, PABP1 was also 
divided into several domains, whereby identification of the respective 
subdomains was guided by bioinformatics analysis of the predicted 
motifs (for example, RNA Recognition Motifs). 
 
The initial investigations used Surface Plasmon Resonance as a means 
to scan domains of PABP1 for binding to eIF4E4(iv). For these 
experiments, Leishmania eIF4E4(iv) was immobilized on the SPR chip 
surface using amine coupling. The initial qualitative observations using 
Yes/No Binding assays provided an indication of which PABP1 domains 
would bind to eIF4E4(iv). The Yes/No Binding experiments suggested 
that the PABP1 C-terminal domains (C, G and J), as well as the full-length 
protein, bind to eIF4E4(iv). There was also a positive signal for one of the 
N-terminal domains (A), but the data obtained were not unequivocally 
clear. Under the conditions used in these initial scanning experiments, 
the sensorgrams lacked a satisfactory dissociation phase. This problem 
can arise from nonspecific binding and subsequent, more detailed, 
investigations led to significant improvements in this part of the binding 
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profile. The optimization experimental conditions (flow rate, buffers 
used, temperature) reduced the contribution of non-specific binding, 
although it did not improve significantly the dissociation phase. 
 
MST experiments were used seeking to further investigate the binding 
between eIF4E4(iv) and the various PABP1 domains. The MST data 
provided more detailed information regarding protein binding, and the 
results agreed with what was observed in the SPR experiments, with the 
full-length PABP1 and its C-terminal domains displaying binding to 
eIF4E4(iv). 
 
In order to further test for protein-protein interactions, deletion 
constructs were prepared (PABP1ΔA, PABP1ΔC and PABP1ΔJ), where the 
C-terminal domains were absent. It was predicted on the basis of the 
earlier experiments that deletion of the C-terminal region would abolish 
binding between the deletion constructs and eIF4E4(iv), and this 
hypothesis was confirmed experimentally. 
 
The interaction data obtained in the MST experiments gave a strong 
indication that the PABP1 C-terminal is involved in binding to eIF4E4(iv). 
In order to investigate the structural basis of this binding, NMR and 
crystallographic experiments were performed. As mentioned in the 
results chapter, the crystallographic work was performed by Dr Maja 
Firczuk in collaboration with Prof Alex Cameron’s group. 
 
Initially, the first NMR experiments attempted involved the acquisition of 
2D {1H-15N}-HSQC spectra. Titration of an isotopically labelled target with 
an unlabelled ligand provided a means to determine if binding was taking 
place. 
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The experiments involved first the titration of isotopically labelled 
PABP1(J) with unlabelled eIF4E4(iv). These experiments showed very 
clearly that a number of peaks disappeared (shifted) in response to the 
titration, indicating that binding was happening between the two 
proteins. Moreover, identification of the chemical shift perturbations 
(CFPs) indicated which amino acid residues were involved in binding. 
Similarly, isotopically labelled eIF4E4(iv) was titrated with unlabelled 
PABP1, and the occurrence of CSPs again confirmed that specific 
interactions had taken place. 
 
In this form of experiment, two extreme types of behaviour can be 
observed. Where binding is weak and there is fast exchange, a single peak 
appears that is a weighted average of the two states, and this 
progressively moves position over the range of the titration (Figure 63). 
Where there is strong binding, there is slow exchange between bound and 
free states, giving rise to changes in the relative intensity of two distinct 
positions as the ligand concentration is titrated (Figure 64). Where these 
relatively simple types of behaviour are observed, it is possible to obtain 
information on the system affinity. However, in the case of the 
eIF4E4(iv)/PABP1(J) pair, an intermediate type of behaviour is observed, 
in which the peaks disappear, and reappear close to ligand saturation, 
making it difficult to calculate affinity on the basis of the titration data. 
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Figure 63: Illustration of chemical shift perturbation in a fast-exchange system, with 
peak slowly changing its position. 
 
 
Figure 64: Illustration of chemical shift perturbation in a slow-exchange system, with 
peak intensity decreasing in the initial position; and increasing in a new, final position. 
 
Even though no accurate quantitative data could be obtained from the 
HSQC data, it was possible to determine the identity of each peak via 
triple resonance experiments, thus leading to the characterization of 
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amino acid residues that are either directly involved in, or whose 
environment is affected by, binding interactions. 
 
The spectra assignment revealed that the peaks that disappeared in the 
titration experiments corresponded to the MLLE domain and PAM2 motif, 
for PABP1 and eIF4E4(iv), respectively.  
 
By combining the NMR data with crystallographic data, it was possible to 
observe that both agreed in assignment of the binding motifs involved in 
eIF4E4(iv)/PABP1 binding. The MLLE/PAM2 type of interaction has been 
described previously as mediating interactions between other pairs of 
proteins. Indeed, PABC domains in other proteins have been described 
previously (KOZLOV 2010; XIE, 2014) as MLLE-containing domains that 
interact with several partners. However, the interaction between eIF4E4 
and PABP1 has not previously been described in detail. The presence of 
PAM2 motif in the unique N-terminal sequence of eIF4E4 highlights the 
importance of this segment in the interaction with PABP1 and suggests 
an explanation for its existence. The present study has also revealed that 
only one of the PAM2 or PAM2-like sequences in eIF4E4 is involved in 
PABP1 binding. 
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Table 7:  eIF4E4 aminoacid residues and corresponding PABP1 aminoacid residues 
involved in the PAM2/MLLE interaction. 
eIF4E4 a.a. residue Interacting PABP1 a.a. residue 
M140 F525, M528, A550 
N141 E527 
P142 V553, H557 
N143 V553, H557, K520 
A144 G523, M524 
T145 G523 
E146 K520, P519 
F147 G523, P519, A500, D504, G503, T522, L526,  
M148 - 
P149 D504 
 
 
It was also possible to obtain information about the molecular principles 
underpinning binding between eIF4E4 and PABP1. Analysis of the NMR 
and crystallographic data, using electrostatic and hydrophobicity maps, 
indicates that the main driving force for complex formation is through 
the association of hydrophobic regions of multiple amino acid side 
chains, with two hydrophobic pockets in PABP1 being particularly 
important. 
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Figure 65: (A) PABP1(J) crystal structure with residues involved in binding to eIF4E4(iv) 
highlighted in blue; (B) PABP1(J)/eIF4E4(iv) peptide hydrophobicity map; (C) 
PABP1(J)/eIF4E4(iv) peptide electrostatic map (D) PABP1(J)/eIF4E4(iv) crystal structure 
with eIF4E4(iv) residues involved in binding to PABP1 highlighted; (E) eIF4E4(iv) peptide 
hydrophobicity map and (F) eIF4E4(iv) peptide electrostatic map. 
 
Our investigation also looked into the eIF4G3-eIF4E4-PABP1 interaction. 
MST data were obtained using eIF4G3, eIF4E4(iv), PABP1 FL, PABP1(J) and 
the {eIF4E4(v)/PABP1(J)} complex. The rationale for these choices lies in 
the respective protein architectures. eIF4E4(iv) contains only the unique 
N-terminal that we found to bind to PABP1, so it should not bind to eIF4G3, 
serving as a negative control. Similarly, PABP1(J) contains only the PABC 
domain that binds to eIF4E4(iv), and which is not expected to bind to 
eIF4G3. eIF4E4(v) contains a region that is predicted on the basis of 
bioinformatics to contain potential eIF4G3-binding sites, and PABP1 FL 
retains all of the relevant natural binding sites. It was not found possible 
to express and purify eIF4E4(v) on its own, but its co-production with 
PABP1(J) was successful. 
 
The MST experiments did not detect binding between eIF4G3 and 
eIF4E4(iv), or between eIF4G3 and PABP1 FL. The experiments 
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investigating binding between eIF4G3 and PABP1(J) also did not detect 
any interaction. However, it was possible to observe binding between 
eIF4G3 and {eIF4E4(v)/PABP1(J)}. Considering the fact that no binding 
could be detected between eIF4G3 and PABP1(J), eIF4E4(v) must be 
responsible for the interaction between eIF4G3 and eIF4E4(v)/PABP1(J). 
 
These data indicate that in Trypanosomatids, the translation initiation 
complex displays an alternative architecture, with eIF4E4 binding to 
PABP1 and eIF4G3, but with no (or very weak) interaction between PABP1 
and eIF4G3 (Figure 66). 
 
 
Figure 66: In trypanosomatids, eIF4E4 is the “scaffolding” component in the cap-binding 
complex. (A) The data obtained in this work indicate that Leishmania eIF4E4 interacts 
in specific manner with PABP1 and eIF4G3, while we were not able to detect interaction 
between PABP1 and eIF4G3. (B) In other known eukaryotic cap-binding complexes, 
eIF4G is the main scaffolding protein. 
 
Finally, this study has focused on key interactions and structures 
underpinning the unique architecture of the Leishmania eIF4E4-PABP1-
eIF4G3 biomolecular chain that links the 5’ and 3’ ends of trypanosomatid 
mRNAs. Future work will be required to increase our understanding of 
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the range of interactions involving other translation factors in 
trypanosomatid translation initiation, such as the DEAD-box RNA-
binding protein eIF4A. 
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Chapter 8 – Conclusions 
 
This study set out to primarily to investigate and analyze the interaction 
between two translation initiation factors from the trypanosomatid 
Leishmania major, i.e. eIF4E4 and PABP1. 
 
The initial strategy involved the investigation of the unique N-terminal 
sequence from eIF4E4, and its interaction with different domains of 
PABP1. Within the eIF4E4 N-terminal, a short 86 amino acid sequence 
was described (ZINOVIEV, 2011) to be required for binding to PABP1, and 
this sequence, denominated in this work eIF4E4(iv), was used as a 
starting point. 
 
PABP1 was divided into several shorter domains that correspond to 
different parts of its architecture, and these domains were used in 
interaction experiments with eIF4E4(iv). 
 
The SPR experiments gave initial, although not completely unequivocal 
results regarding the binding regions in PABP1, however they pointed 
towards involvement of the C-terminal region of PABP1. 
 
MST experiments provided additional information, displaying the 
relative affinities of the different PABP1 domains, most importantly 
pointing to the involvement of the PABP1 C-terminal in binding to 
eIF4E4(iv). Experiments with PABP1 constructs in which the C-terminal 
was deleted showed that binding to eIF4E4(iv) is abolished with the 
removal of PABP1 C-terminal. 
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NMR experiments were performed in order to further investigate binding 
and also identify the binding motif, using isotopically labelled eIF4E4(iv) 
and PABP1(J). 2D NMR data revealed that the proteins undergo a specific 
interaction, whereby triple resonance experiments mapped potential 
binding motifs. 
 
Motif mapping revealed that the binding takes place through a 
MLLE/PAM2 interaction, with the PABP1 PABC domain containing the 
MLLE domain, and the eIF4E4 N-terminal the PAM2 motif. 
 
The combination of NMR data with the data obtained through X-ray 
crystallography provided mutually consistent results, revealing that the 
MLLE domain corresponds to the typical structure (XIE, 2014; KOZLOV 
2010) for a MLLE/PAM2 interaction. These results have therefore 
described in detail the characteristics of this unique Trypanosomatid 
eIF4E4 N-terminal region and its interactions with PABP1. The NMR data 
revealed that eIF4E4 N-terminal is naturally disordered, but its 
interaction with PABP1 induces at least a partial folding in this region.    
 
Additionally, the interaction of eIF4G3 and eIF4E4 and PABP1 was 
investigated by MST. Our MST results revealed interaction between 
eIF4G3 and eIF4E4, but we were not able to detect interaction between 
eIF4G3 and PABP1 (indicating that this interaction might not exist or be 
very weak). These data suggest that in Trypanosomatids, the translation 
initiation complex might display an alternative architecture, with eIF4E4 
binding to PABP1 and eIF4G3, but without interaction between PABP1 and 
eIF4G3 (see Figure 67).  
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Chapter 9 – Annexes 
The following data is presented in this Chapter: 
 
-Primers List 
-Plasmid maps and gene blocks 
-Proteins and domains sequences 
-SPR sensorgrams and protein concentrations used  
-Microscale thermophoresis data 
-Nuclear Magnetic Resonance Data 
-Crystallographic data 
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PRIMERS LIST 
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Name Primer Sequence Use 
663_pET22b_NdeI_F ATATACATCATATGAAAATAAA
AACAGGTGCACGCATC 
eIF4E4-12His in pEt22b 
vector Forward primer. 
663_pET22b_HindIII_R ATATACAAGCTTTGGGGTTAAC
CTTAATAGCGACGACGG 
eIF4E4-12His in pEt22b 
vector Reverse primer. 
883_pET22b_NdeI_F ATATATCCATATGATGAAA
ATAAAAACAGGTGCACGC 
PABP1-12His in pEt22b 
vector Forward primer. 
883_pET22b_HindIII_R ATATATCAAGCTTTGGGGT
TAACCTTACGCAGTCTGG 
PABP1-12His in pEt22b 
vector Reverse primer. 
663_MBP_BamHI_F ATATACGGATCCATGAGCA
CTCCGTTAGACGTTCGT 
 
eIF4E4-6His in MBP 
fusion vector Forward 
primer. 
663_MBP_HindIII_R ATATACAAGCTTTGGGGTT
AACCTTAATAGCGACGACG
G 
 
eIF4E4-6His in MBP 
fusion vector Reverse 
primer. 
883_MBP_BamHI_F ATATACGGATCCATGGCAG
CAGCAGTCCAAGAAGCA 
 
PABP1-6His in MBP 
fusion vector Forward 
primer. 
883_MBP_HindIII_R ATATATCAAGCTTTGGGGT
TAACCTTACGCAGTCTGG 
 
PABP1-6His in MBP 
fusion vector Reverse 
primer. 
 
 
 
 
 
 
 
 
 
 
 
Chapter 9 | Annexes 
 - 110 - 
PLASMID MAPS AND GENE BLOCKS 
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>eIF4E4(iv) Plasmid map – pET22b 
 
>eIF4E4(iv) Gene Block 
 
ACTTTAAGAAGGAGATATACATATGAATCCGAACGCAACCGAGTTCATGCCGGGTC
GTCGTAACGGCCCAGATGGCGGCCTGGAAGCCCTGCCAACCAGCACCGCGGACATG
GAATTGGCAAAAACGCCGGCTGGTGCGGCTGCAGCGGCCGTTCATGCGCCGTCCCT
GCCGGGTGCGGTGCGTCGTTCGCTGCAAAACAGCCCGATCATTCAGCCGAGCCGTC
TGAGCGTCAAAAGCGCCAGCGAGATCGAAGCGATTAGCAAAAACAGCGCCCTGAAT
GCACATCACCACCACCACCATCACCACCACCATCACCACTGTTGACCATGGATATC
GGAATTAATTCGGATC 
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>PABP1 and Domains Plasmid map – pET22b 
 
  
 
Chapter 9 | Annexes 
 - 113 - 
>eIF4E4-MBP Plasmid map  
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>PABP1-MBP Plasmid map  
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PROTEINS AND DOMAINS SEQUENCES 
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>Leish major PABP1 Full length 
MAAAVQEAAAPVAHQPQMDKPMQIASIYVGDLDATINEPQLVELFKPFGTILNVRV
CRDIITQRSLGYGYVNFDNHDSAEKAIESMNFKRVGDKCVRLMWQQRDPALRYSGN
GNVFVKNLEKDVDSKSLHDIFTKFGSILSCKVMQDEEGKSRGYGFVHFKDETSAKD
AIVKMNGAADHASEDKKALYVANFIRRNARLAALVANFTNVYIKQVLPTVNKDVIE
KFFAKFGGITSAAACKDKSGRVFAFCNFEKHDDAVKAVEAMHDHHIDGITAPGEKL
YVQRAQPRSERLIALRQKYMQHQALGNNLYVRNFDPEFTGADLLELFKEYGEVKSC
RVMVSESGVSRGFGFVSFSNADEANAALREMNGRMLNGKPLIVNIAQRRDQRYTML
RLQFQQRLQMMMRQMHQPMPFVGSQGRPMRGRGGRQQLGGRAQGHPMPMPSPQQPQ
APAQPQGFATPSAVGFVQATPKHSPGDVPETPPLPPITPQELESMSPQEQRAALGD 
RLFLKVYEIAPELAPKITGMFLEMKPKEAYELLNDQKRLEERVTEALCVLKAHQTA 
 
>Leish major PABP1(A) 
MAAAVQEAAAPVAHQPQMDKPMQIASIYVGDLDATINEPQLVELFKPFGTILNVRV
CRDIITQRSLGYGYVNFDNHDSAEKAIESMNFKRVGDKCVRLMWQQRDPALRYSGN
GNVFVKNLEKDVDSKSLHDIFTKFGSILSCKVMQDEEGKSRGYGFVHFKDETSAKD
AIVKMNGAADHASEDKKALYVANFIRRNARLA 
 
 
>Leish major PABP1 (B) 
ALVANFTNVYIKQVLPTVNKDVIEKFFAKFGGITSAAACKDKSGRVFAFCNFEKHD
DAVKAVEAMHDHHIDGITAPGEKLYVQRAQPRSERLIALRQKYMQHQALGNNLYVR
NFDPEFTGADLLELFKEYGEVKSCRVMVSESGVSRGFGFVSFSNADEANAALREMN
GRMLNGKPLIVNIAQR 
 
 
>Leish major PABP1 (C) 
RDQRYTMLRLQFQQRLQMMMRQMHQPMPFVGSQGRPMRGRGGRQQLGGRAQGHPMP
MPSPQQPQAPAQPQGFATPSAVGFVQATPKHSPGDVPETPPLPPITPQELESMSPQ
EQRAALGDRLFLKVYEIAPELAPKITGMFLEMKPKEAYELLNDQKRLEERVTEALC
VLKAHQTA 
 
>Leish major PABP1(D) 
MAAAVQEAAAPVAHQPQMDKPMQIASIYVGDLDATINEPQLVELFKPFGTILNVRV
CRDIITQRSLGYGYVNFDNHDSAEKAIESMNFKRVGDKCVRLMWQQRDPALR 
 
>Leish major PABP1(E) 
YSGNGNVFVKNLEKDVDSKSLHDIFTKFGSILSCKVMQDEEGKSRGYGFVHFKDET
SAKDAIVKMNGAADHASEDKKALYVANFIRRNARLAALVANFTNVYIKQVLPTVNK
 
Chapter 9 | Annexes 
 - 117 - 
DVIEKFFAKFGGITSAAACKDKSGRVFAFCNFEKHDDAVKAVEAMHDHHIDGITAP
GEKLYVQRAQPRSERLIALRQ 
>Leish major PABP1(F) 
KYMQHQALGNNLYVRNFDPEFTGADLLELFKEYGEVKSCRVMVSESGVSRGFGFVS
FSNADEANAALREMNGRMLNGKPLIVNIAQRRDQRYTMLRLQFQQRLQMMMRQMHQ
PMPFVGSQGRPMRGRGGRQQLGGRAQGH 
 
>Leish major PABP1(G) 
PMPMPSPQQPQAPAQPQGFATPSAVGFVQATPKHSPGDVPETPPLPPITPQELESM
SPQEQRAALGDRLFLKVYEIAPELAPKITGMFLEMKPKEAYELLNDQKRLEERVTE
ALCVLKAHQTA 
 
>Leish major PABP1(H) 
RRDQRYTMLRLQFQQRLQMMMRQMHQPMPFVGSQGRPMRGRGGRQQLGGRAQGHPM
PMPSPQQPQAPAQPQGFATPSAVGFVQATPKHSPGDVPETPPLPPITP 
 
>Leish major PABP1(I) 
QKYMQHQALGNNLYVRNFDPEFTGADLLELFKEYGEVKSCRVMVSESGVSRGFGFV
SFSNADEANAALREMNGRMLNGKPLIVNIAQRRDQRYTMLRLQFQQRLQMMMRQMH
QPMPFVGSQGRPMRGRGGRQQLGGRAQGHPMPMPSPQQPQAPAQPQGFATPSAVGF
VQATPKHSPGDVPETPPLPPITP 
 
>Leish major PABP1(J) 
LPPITPQELESMSPQEQRAALGDRLFLKVYEIAPELAPKITGMFLEMKPKEAYELL
NDQKRLEERVTEALCVLKAHQTA 
 
>Leish major PABP1(L) 
RYSGNGNVFVKNLEKDVDSKSLHDIFTKFGSILSCKVMQDEEGKSRGYGFVHFKDE
TSAKDAIVKMNGAADHASEDKKALYVANFIRRNARLA 
 
>Leish major PABP1(M) 
LPPITPQELESMSPQEQRAALGDRLFLKVYEIAPELAPKIT 
 
>Leish major PABP1(N) 
GMFLEMKPKEAYELLNDQKRLEERVTEALCVLKAHQTA 
 
>Leish major PABP1(O) 
RAALGDRLFLKVYEIAPELAPKITGMFLEMKPKEA 
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>Leish major PABP1(ΔA) 
AALVANFTNVYIKQVLPTVNKDVIEKFFAKFGGITSAAACKDKSGRVFAFCNFEKH
DDAVKAVEAMHDHHIDGITAPGEKLYVQRAQPRSERLIALRQKYMQHQALGNNLYV
RNFDPEFTGADLLELFKEYGEVKSCRVMVSESGVSRGFGFVSFSNADEANAALREM
NGRMLNGKPLIVNIAQRRDQRYTMLRLQFQQRLQMMMRQMHQPMPFVGSQGRPMRG
RGGRQQLGGRAQGHPMPMPSPQQPQAPAQPQGFATPSAVGFVQATPKHSPGDVPET
PPLPPITPQELESMSPQEQRAALGDRLFLKVYEIAPELAPKITGMFLEMKPKEAYE
LLNDQKRLEERVTEALCVLKAHQTA 
 
>Leish major PABP1(ΔC) 
MAAAVQEAAAPVAHQPQMDKPMQIASIYVGDLDATINEPQLVELFKPFGTILNVRV
CRDIITQRSLGYGYVNFDNHDSAEKAIESMNFKRVGDKCVRLMWQQRDPALRYSGN
GNVFVKNLEKDVDSKSLHDIFTKFGSILSCKVMQDEEGKSRGYGFVHFKDETSAKD
AIVKMNGAADHASEDKKALYVANFIRRNARLAALVANFTNVYIKQVLPTVNKDVIE
KFFAKFGGITSAAACKDKSGRVFAFCNFEKHDDAVKAVEAMHDHHIDGITAPGEKL
YVQRAQPRSERLIALRQKYMQHQALGNNLYVRNFDPEFTGADLLELFKEYGEVKSC
RVMVSESGVSRGFGFVSFSNADEANAALREMNGRMLNGKPLIVNIAQR 
 
>Leish major PABP1(ΔJ) 
MAAAVQEAAAPVAHQPQMDKPMQIASIYVGDLDATINEPQLVELFKPFGTILNVRV
CRDIITQRSLGYGYVNFDNHDSAEKAIESMNFKRVGDKCVRLMWQQRDPALRYSGN
GNVFVKNLEKDVDSKSLHDIFTKFGSILSCKVMQDEEGKSRGYGFVHFKDETSAKD
AIVKMNGAADHASEDKKALYVANFIRRNARLAALVANFTNVYIKQVLPTVNKDVIE
KFFAKFGGITSAAACKDKSGRVFAFCNFEKHDDAVKAVEAMHDHHIDGITAPGEKL
YVQRAQPRSERLIALRQKYMQHQALGNNLYVRNFDPEFTGADLLELFKEYGEVKSC
RVMVSESGVSRGFGFVSFSNADEANAALREMNGRMLNGKPLIVNIAQRRDQRYTML
RLQFQQRLQMMMRQMHQPMPFVGSQGRPMRGRGGRQQLGGRAQGHPMPMPSPQQPQ
APAQPQGFATPSAVGFVQATPKHSPGDVPETPPL 
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>Leish major eIF4E4   
MSTPLDVRAAEYSPSFAVTMKKTVAAAPPKSPAPAKSKISVTRTGVNTTYPMPPPM
PEKNYAPFFAEGCQTIAASKASMPPVQPASPLPPMHSAPPTASVVSNSIPPSSPAT
APGERSPAVAARSVPTRFSPATVPRHHMNPNATEFMPGRRNGPDGGLEALPTSTAD
MELAKTPAGAAAAAVHAPSLPGAVRRSLQNSPIIQPSRLSVKSASEIEAISKNSAL
NAAAAAYVPQRTLARVVLTQPSPLALAPSEDPAKNNIEMMLDDLWCLFYLPTTLGE
NIKEEDYNPTLVFRVDSILTFWRVVNNIAAPSELQLSTLYLFRDGIDPKWEDPANR
DGGIVKVKATAAQVDEAWELLLCRTIGDSWSPSVRETVNGVVLKVRERAYWLELWV
TKNSSALQKDLAELWHPILGASFATTYLTHAMMQERSHAAAALAAEKQKKNRRRY 
 
>Leish major eIF4E4(iv) 
MNPNATEFMPGRRNGPDGGLEALPTSTADMELAKTPAGAAAAAVHAPSLPGAVRRS
LQNSPIIQPSRLSVKSASEIEAISKNSALNA 
 
>Leish major eIF4E4(v) 
MNPNATEFMPGRRNGPDGGLEALPTSTADMELAKTPAGAAAAAVHAPSLPGAVRRS
LQNSPIIQPSRLSVKSASEIEAISKNSALNAAAAAYVPQRTLARVVLTQPSPLALA
PSEDPAKNNIEMMLDDLWCLFYLPTTLGENIKEEDYNPTLVFRVDSILTFWRVVNN
IAAPSELQLSTLYLFRDGIDPKWEDPANRDGGIVKVKATAAQVDEAWELLLCRTIG
DSWSPSVRETVNGVVLKVRERAYWLELWVTKNSSALQKDLAELWHPILGASFATTY
LTHAMMQERSHAAAALAAEKQKKNRRRY 
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SPR SENSORGRAMS 
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eIF4E4(iv)/ PABP full length – Initial experiment 
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eIF4E4(iv)/ PABP full length – Optimized experiment 
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eIF4E4(iv)/ PABP1(A) 
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eIF4E4(iv)/ PABP1(B) 
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eIF4E4(iv)/ PABP1(C) 
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eIF4E4(iv)/ PABP1(D) 
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eIF4E4(iv)/ PABP1(E) 
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eIF4E4(iv)/ PABP1(F) 
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eIF4E4(iv)/ PABP1(G)  
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eIF4E4(iv)/ PABP1(I) 
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eIF4E4(iv)/ PABP1(J) 
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Protein Concentrations for Binding Affinity Experiments 
PABP1/µM 
PABP1 
Optimized/µM PABP1(A)/µM PABP1(B)/µM PABP1(C)/µM PABP1(D)/µM 
1.55 1.49 21.20 1.64 2.31 21.14 
0.78 0.74 10.60 0.82 1.16 10.57 
0.39 0.37 5.30 0.41 0.58 5.29 
0.19 0.19 2.65 0.21 0.29 2.64 
0.10 0.09 1.33 0.10 0.14 1.32 
0.05 0.02 0.66 0.05 0.07 0.66 
      
PABP1(E)/µM PABP1(F)/µM PABP1(G)/µM PABP1(I)/µM PABP1(J)/µM  
8.99 21.18 22.08 20.09 21.20 
 
4.50 10.59 11.04 10.05 10.60  
2.25 5.30 5.52 5.02 5.30  
1.12 2.65 2.76 2.51 2.65  
0.56 1.32 1.38 1.26 1.33  
0.28 0.66 0.69 0.63 0.66 
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MICROSCALE THERMOPHORESIS DATA 
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eIF4E4(iv)/ PABP1 full length 
 
 
eIF4E4(iv)/ PABP1(A) 
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eIF4E4(iv)/ PABP1(B) 
 
 
eIF4E4(iv)/ PABP1(C) 
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eIF4E4(iv)/ PABP1(D) 
 
 
eIF4E4(iv)/ PABP1(F) 
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eIF4E4(iv)/ PABP1(G) 
 
 
eIF4E4(iv)/ PABP1(I) 
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eIF4E4(iv)/ PABP1(J) 
 
 
 
eIF4E4(iv)/ PABP1(L) 
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eIF4E4(iv)/ PABP1(M) 
 
 
 
 
eIF4E4(iv)/ PABP1(N) 
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eIF4E4(iv)/ PABP1(O) 
 
 
eIF4E4(iv)/ PABP1(ΔC) 
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eIF4E4(iv)/ PABP1(ΔJ) 
 
 
eIF4E4(iv)/BSA 
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eIF4G3+eIF4E4(iv) 
 
 
eIF4G3+ PABP1 FL 
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eIF4G3+ PABP1(J) 
 
 
 
 
eIF4G3+{eIF4E4(v)/ PABP1(J)} complex 
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NUCLEAR MAGNETIC RESONANCE 
SPECTRA 
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1H Isotopically labelled eIF4E4(iv) 
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1H Isotopically labelled PABP1(J) 
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{1H-15N}-HSQC - Isotopically labelled eIF4E4(iv) + unlabelled PABP1(J) 
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{1H-15N}-HSQC Isotopically labelled PABP1(J) + unlabelled eIF4E4(iv) 
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{1H-15N}-HSQC Isotopically labelled PABP1(J) + unlabelled eIF4E4-
PAM2 peptide 
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PABP1(J) Structure 
 
 
 
 
 
 
 
 
 
 
 
 
 
PABP1(J) Structure+ PAM2 peptide 
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PABP1(J) Dimensions 
 
PABP1(J) 𝝰-helices vectors 
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PABP1(J)/eIFE4(iv) hydrophobicity map 
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PABP1(J)/eIFE4(iv) electrostatic map 
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